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ABSTRACT 
THE ABILITY TO GENERATE DIFFERENTIATED AND 
SENECESENT PROGENY IS A MAJOR DETERMINANT OF 
BREAST CANCER HETEROGENEITY 
 
Mine Mumcuoğlu 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Dr. Mehmet Öztürk 
August 2009, 124 Pages 
 
 
 
 
Breast cancer displays distinct subtypes, such as luminal A, luminal B, and basal-
like. The prognosis and therapeutic response of each subtype is different. The 
mechanisms involved in the generation of these tumor types are poorly understood. 
Our aim was to test whether the ability to generate senescent progeny contributes to 
breast cancer heterogeneity. A panel of 12 breast cancer cell lines, 31 isogenic 
clones, and 12 breast tumors were used. We classified breast cancer cell lines into 
senescent cell progenitor (SCP) and immortal cell progenitor (ICP) subtypes. All 
ER+ cell lines tested and some ER-positive (ER+) breast tumors displayed 
senescence. Acute loss and tamoxifen-mediated inactivation of ER triggered a robust 
senescence response in SCP type T47D cell line.  In contrast, ER-overexpression, 
estrogen treatment and p21
Cip1
 knockdown inhibited senescence. Neutralization of 
reactive oxygen species also abolished senescence. Breast cancer cell subtypes 
displayed divergent ability to produce differentiated progeny. The SCP subtype cells 
produced CD24+ or ER+ luminal-like and ASMA+ myoepithelial-like progeny, in 
addition to CD44+ stem/progenitor-like cells. In contrast, ICP cell lines acted as 
differentiation-defective stem/progenitor cells. Some cell lines generated only 
CD44+/CD24-/ ER-/ASMA- progenitor/stem-like cells, and others only CD24+/ER- 
luminal-like, but not ASMA+ myoepithelial-like cells. SCP cell lines were less 
tumorigenic, and they clustered with luminal A/normal like tumors. In contrast, ICP 
subtypes were more tumorigenic, and they clustered together with basal/luminal B 
tumors. Our results show that breast cancer cell lines clustering with luminal 
A/normal-like and basal/luminal B tumors respectively, differ from each other by the 
ability to generate differentiated and senescence-arrested progeny.  
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ÖZET 
FARKLILAŞMIŞ VE SENESANT PROJENİTÖR OLUŞTURMA 
POTANSİYELİ MEME KANSERİNİN HETEROJEN YAPISININ 
BAŞLICA BELİRLEYİCİLERİNDENDİR 
 
Mine Mumcuoğlu 
Moleküler Biyoloji ve Genetik Doktorasi 
Tez Yöneticisi: Dr. Mehmet Öztürk 
Agostos 2009, 124 Sayfa 
 
 
 
Meme kanseri luminal A, lüminal B ve basal-benzeri gibi farklı alttürlerden 
oluşmaktadır. Her alt türün prognozu ve tedaviye yanıtı farklıdır. Söz konusu alt 
türlerin oluşumunde yer alan mekanizmalar iyi bilinmemektedir. Bu çalışmanın 
amacı, hücre yaşlanması ya da senesansın meme kanerinin heterojen yapısına 
herhangi bir katkıda bulunup bulunmadığını araştırmaktı. Bu amaçla 12 meme 
kanseri hücre hattı, 31 izogenik hücre klonu ve 12 meme tümörü incelendi. Meme 
kanseri hücre hatlarını senesant hücre (SCP) ve ölümsüz hücre (ICP) projenitörleri 
olarak iki türde sınıflandırdık. Test edilen tüm östrojen almaç-pozitif (ER+) hücre 
hatları ve bazı ER+ meme tümörleri senesans gösterdi. Estrojen almacının akut kaybı 
ve tamoksifenle etkisizleştirilmesi SCP türü T47D hücre hattında güçlü bir senesans 
yanıtına yol açtı. Buna karşılık, östrojenle muamele, estrojen almacının aşırı ifadesi 
ve p21
Cip1
 geninin “knock-down” yöntemi ile etkisizleştirilmesi senesensı baskıladı. 
Ayrıca, reaktif oksijen türlerinin N-asetil sistein ile nötralize edilmesi de senesens 
yanıtını engelledi. Meme kanseri alt türleri farklılaşmış projeni oluşturma potansiyeli 
açısından farklılık gösterdi. SCP alttürü hücreler, CD44+ kök/projenitör hücrelere ek 
olarak, CD24+ veya ER+ lüminal-benzeri, ve ASMA+ miyoepitel-benzeri hücreler 
ürettiler. Buna karşılk, ICP hücre hatları farklılaşmada kusurlu olan kök/projenitör 
hücreler olarak davrandılar. Bazı hücre hatları sadece CD44+/CD24-/ ER-/ASMA-  
projenitör/kök-benzeri hücreler üretirken, diğerleri CD24+/ER- lüminal-benzeri 
hücreler ürettiler. Ancak ASMA+ miyoepitel-benzeri hücre üretemediler. SCP hücre 
hatları daha az tümörijenik olup luminal A/normal-benzeri tümörlerle kümeleştiler. 
Buna karşılık ICP alttürü hücreler daha fazla tümörijenik olup bazal/lüminal B 
tümörlerle kümeleştiler. Sonuçlarımız lüminal A/normal-benzeri ve bazal/lüminal B 
tümörlerle kümeleşen meme kanseri hücre hatlarının farklılaşma ve senesensa 
girebilme özellikleri açısından birbirlerinden ayrıldıklarını göstermiştir.  
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CHAPTER 1.       INTRODUCTION 
 
 
1.1 Breast Cancer 
Development of breast starts during embryonic period. Ductal morphogenesis begins 
by a bud-like structure with branching, and then continues with elongation and 
canalization. Both smooth muscle actin and cytokeratin expressing basal cells appear 
at the end of the second trimester. Adult breast is composed of two types of cells: 
Myoepithelial cells and secretory luminal cells. It is possible to categorize different 
steps clinically and histopathologically during progression to malignancy. Ductal 
hyperplasia is accepted as a very early step of the malignancy. In this stage, cells are 
cytologically benign. Transformation from hyperplasia to atypical hyperplasia 
presents increased risk for breast cancer. The following step is ductal or lobular 
carcinoma in situ. Cells in this step show cytological characteristics of malignancy, 
but without stromal invasion across the basement membrane. Tumor becomes 
invasive when the cells detach from basement and invade the stroma. When the cells 
reach the blood and lymph vessels, it can easily metastasize distant organs and 
locoregional lymph nodes (Kenemans et al., 2004). 
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Figure 1: Mammary gland, terminal ductal-lobular unit. (Dimri et al., 2005) 
 
Breast cancer appears as multistep process where accumulation of various genetic 
alterations can cause transformation of normal cells via steps of hyperplasia, 
premalignant change and in situ carcinoma (Beckmann et al, 1997). In recent years, 
it has been suggested that besides intrinsic malignant properties of tumor epithelial 
cells, other factors such as microenvironmental changes may play role in 
tumorigenesis (Hu and Polyak, 2008) 
1.1.1 Epidemiology 
Breast cancer is the most common malignancy and the second leading cause of 
cancer deaths in women (after lung cancer).  Breast cancer comprises 15% of all 
female cancers. During 2009, over 190,000 new cases of invasive breast cancer are 
expected to occur among women in the US; about 1,900 for men. (Source: American 
cancer society). 
 
Age is one of the most important risk factors for breast cancer, beside gender. Breast 
cancer incidence increases with age. Until menopause, disease incidence doubles 
every 10 years then slows down significantly.  
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Geographical variations also affect incidence and mortality. The difference between 
Western and Far East countries is fivefold, but it is declining. 
Reproductive history could affect the incidence such as long menstrual history (early 
menarche and/or late menopause), recent use of oral contraceptives, nulliparity or 
having a first child after age 30. 
 
In Western countries, 10% of breast cancer is due to genetic predisposition. Breast 
cancer susceptibility genes, BRCA1 and BRCA2, have been identified as a 
substantial proportion of high-risk families. In some populations, certain mutations 
occur at high frequency. For example, 2% of Ashkenazi Jewish women carry either 
BRCA1 185 del AG (deletion of two base pairs at position 185), BRCA1 5382 ins C 
(insertion of an extra base pair at position 5382) or BRCA 6174 del T (deletion of a 
single base pair at position 6174), while BRCA2 999 del 5 (deletion of five base 
pairs at position 999) accounts for about half of all familial breast cancer in Iceland. 
Li-Fraumeni and Cowden’s syndromes, associated with inherited mutations in p53 
and PTEN respectively, carry high risk of breast cancer but both are rare (McPherson 
et al., 2000). 
 
Other risk factors of breast cancer include high-dose radiation to the chest, being 
overweight or obese after menopause, use of hormone replacement therapy 
(especially combined estrogen and progestin therapy), physical inactivity, and 
consumption of one or more alcoholic beverages per day. 
1.1.2 Molecular pathogenesis 
Hereditary breast cancer is characterized by an inherited susceptibility to breast 
cancer on the basis of an identified germline mutation in one allele of a high 
penetrance susceptibility gene (such as BRCA1, BRCA2, CHEK2, TP53 or PTEN). 
Inactivation of the second allele of these tumor suppressor genes would be an early 
event in this oncogenic pathway (Knudson’s “two-hit” model).  
 
Sporadic breast cancers result from a serial stepwise accumulation of acquired and 
uncorrected mutations in somatic genes, without any germline mutation playing a 
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role. Mutational activation of oncogenes, often coupled with non-mutational 
inactivation of tumor suppressor genes, is probably an early event in sporadic 
tumors, followed by more, independent mutations in at least four or five other genes 
(the chronological order is not important). Oncogenes that have been reported to play 
an early role in sporadic breast cancer are MYC, CCND1 (Cyclin D1) and ERBB2 
(HER2/neu). In sporadic breast cancer, mutational inactivation of BRCA1/2 is rare, 
as inactivation requires both gene copies to be mutated or totally be deleted. 
However, non-mutational functional suppression could result from various 
mechanisms, such as hypermethylation of the BRCA1 promoter or binding of 
BRCA2 by EMSY (Kenemans et al., 2004). 
 
Until recently, breast cancer tumorigenesis has been described by a multi-step 
progression model. One or more distinct mutations in regulatory genes are associated 
with each of these steps (Beckmann et al, 1997). But recently, Melchor and Benítez 
proposed integrative hypothesis about origin and development of hereditary and 
sporadic breast cancer subtypes. In their approach they try to explain breast cancer 
tumorigenesis by combination of the cancer stem cell hypothesis (for the 
carcinogenesis processes) and the clonal selection model (in terms of tumor 
development). (Melchor and Benitez, 2008)  
ER and breast cancer: 
Estrogens are steroid hormones that play significant role in mammary gland 
development and physiology. They are produced mainly by developing follicles in 
the ovary which are operative only during menstrual life in women. Other 
endogenous source of estrogen is peripheral conversion of adrenal derived-androgens 
to estrogen in fat cells. Estrogen can also be supplied by exogenous sources such as 
oral contraceptives during reproductive years or hormone replacement therapies. 
Until 1970’s the use of DES (Diethyl Stilbestrol) during pregnancy was another 
exogenous source for estradiol. Later, it was shown that women who use DES have 
an increasing risk for development of breast cancer (Henderson et al., 1988).   
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Despite its role in normal mammary gland physiology, estrogen is implicated in 
development and progression of breast cancer based on the data both from clinical 
and animal studies (Henderson and Feigelson, 2000). Estrogen mediates its 
proliferative effect through an intracellular receptor, the estrogen receptor (ER). 
Steroid hormones are lipophilic and they enter the cell by diffusing through the 
plasma and nuclear membranes. Once estrogen enters the nucleus, it binds to ER. 
Estrogen binding to ER transforms the receptor to an active transcription factor, 
allowing it to bind estrogen response element (ERE) regulatory sequences in target 
genes, and regulate the transcription of target genes in the nucleus. 
 
 
 
Figure 2: A subcellular model of estradiol (E2) action in target tissue. (Morrow and 
Jordan, 1999) 
 
There are two receptors for estradiol, ERα and ERβ, which have distinct tissue 
expression patterns (Couse JF et al., 1999). Both ER receptors are members of the 
steroid/thyroid hormone nuclear receptor superfamily and are homologous in their 
DNA-binding and steroid binding domains. But ERβ gene is smaller, encoding a 
smaller protein and is located in a different chromosomal location. (Kumar V et al., 
1987; Enmark E et al., 1997)  
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Since ER mediates estrogen activity, researchers have heavily studied the role of ER 
in breast cancer. Increased ER expression is probably one of the earliest changes 
occurring during breast cancer tumorigenesis. Increased ER expression has been 
shown in benign breast epithelium of women diagnosed to have breast cancer (Khan 
SA et al., 1994) and in the very early stages of ductal hyperplasia (Allred DC et al., 
2001, Shoker BS et al., 1999). Another study also showed that breast tissue of 
Japanese women from a population with high risk of breast cancer expresses higher 
percentage of ERα compared to those who have a low risk of the disease (Lawson JS 
et al., 1999). These and many other studies have indicated that ER receptor status is a 
very important factor for evaluation of breast cancer patients. For example ER– (ER 
negative) breast tumor patients have early recurrence and poor survival compared to 
ER+ (ER positive) breast tumor patients. In addition, ER+ patients confer good 
response to endocrine therapy compared to ER- counterparts. 
 
In clinics, several estrogen antagonists have been successfully used in breast cancer 
therapy. They target estrogen mediated proliferation pathways but their effectiveness 
change in different patients and their mechanism of action is not fully understood. 
There are two groups of antiestrogens: Steroidal and nonsteroidal.  Antiestrogens 
such as ICI 164.384 and ICI 182.780 are steroidal compounds which have only 
antagonistic activities. Nonsteroidal antiestrogen agents such as tamoxifen and 
raloxifen have mixed agonist/antagonist action depending on the cell type. The 
antitumor effects of tamoxifen are thought to be mediated by competitive inhibition 
of estrogen due to its binding to estrogen receptors. As a result, tamoxifen inhibits 
the expression of estrogen-regulated genes. But recent data suggests that tamoxifen 
can cause conformational changes in the ER, change its interaction with specific 
accessory proteins and lead to its recruitment to the transcriptional machinery.  
Epidermal Growth Factor (EGF) family of proteins: 
Besides estrogen, other hormones perform essential roles in mammary gland 
development and also progression of mammary tumorigenesis. It has been shown 
that estrogen affects mammary epithelial cells both directly and indirectly by 
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modulating the expression of growth factors and their receptors. EGF-family of 
peptides is also involved in mammary gland regulation. EGF, Transforming growth 
factor-  (TGFα) and Heregulin are implicated in breast cancer development. 83% of 
human breast tumors express EGF mRNA. 15-30% invasive tumors express EGF 
protein. EGF can promote anchorage dependent growth in mouse and human 
mammary gland. EGF mRNA level is found to be very high in estrogen receptor 
positive breast cancer cell line, T47D (Bowcock AM, 1999). 
Transforming Growth Factor-β (TGFβ): 
Most cells produce Transforming growth factor-β (TGFβ) and its growth receptor 
proteins. TGFβ signaling acts as a regulator in many cellular processes such as cell-
growth regulation, development, morphogenesis, chemotaxis, connective tissue and 
extracellular matrix protein production. TGFβ is also a very important growth 
regulator for mammary gland development and this powerful growth inhibitory 
signal barrier is generally destroyed in cancer cells. Due to its pleiotropic and 
context-dependent effect, animal studies that target TGFβ signaling components gave 
different results about its action on breast cancer development. It is now mostly clear 
that elevated TGFβ plays tumor suppressive function at early stages of breast 
development, whereas it induces a malignant conversion and progression of cancer at 
later stages (Barcellos-Hoff and Akhurst, 2009). 
Insulin-like Growth Factor (IGF): 
It is shown that, there is an association between serum concentrations of insulin-like 
growth factor 1 (IGF1), IGF-binding protein 3 (IGFBP3), and increased risks of 
breast, prostate, colorectal, and lung cancers (Fürstenberger and Senn, 2002).  
Despite some controversies, meta-analysis results suggest correlation between 
circulating IGF1 level and cancer risk in pre-menopausel breast (Werner and 
Bruchim, 2009). IGFs and their binding proteins play role on cell proliferation, 
differentiation, and apoptosis. IGF1R signal transduction causes activation of several 
intracellular signaling pathways, including the Ras/Raf/MAP kinase and the 
phosphoinositide-3 kinase pathways. Moreover interaction between IGF receptors 
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and other cell surface receptors such as the estrogen, integrin, and cytokine receptors 
is important. 
Oncogenes 
Oncogene amplification is frequently found in breast cancer, but only a few of these 
amplified genes are important in breast cancer development, i.e. MYC, Int2, EMS1, 
BCL2, CCND1 and ERBB2. Oncogene amplification is not a very early event, but it 
can be found during DCIS (Ductal carcinoma In Situ) stage (Beckmann et al, 1997). 
Tumor suppressor genes  
The BRCA1 gene is located on chromosome 17q12-21 and participates in many 
transcriptional processes. It interacts with more than 15 different proteins that are 
involved in transcriptional activation or transcriptional repression. It also functions as 
a tumor suppressor and plays a role in apoptosis, DNA recognition and repair. 
Germline mutations in BRCA1 impose high risk to breast and ovarian cancer. In 
sporadic breast cancer, BRCA1 mutation is less frequently seen (Kenemans et al., 
2004).  
The BRCA2 gene which is located on chromosome 13q12-13, codes for a protein 
that play role in DNA repair, cell cycle control and transcription. It is also implicated 
in terminal differentiation of breast epithelial cells. BRCA1 and BRCA2 are high 
penetrance genes for breast cancer. Germ-line mutations of BRCA1 and BRCA2 are 
associated with 40-70% of familial breast cancers, including the hereditary breast 
and/or ovarian cancer sendrome (Beckmann et al, 1997). 
p53 (TP53) is one of the most frequently mutated genes in sporadic human cancer, 
which is located on chromosome 17p13.1. Generally these mutations are point 
mutations that effect sequence-specific DNA binding and activation of p53-
responsive genes. In sporadic breast carcinomas, TP53 mutation is a late event. 
Constitutional mutation of p53 is found in Li-Fraumeni sendrome but it is rare 
(Kenemans et al., 2004). 
Other tumor supressors like Rb, PTEN, CHEK2 are also involved in breast cancer 
pathogenesis. 
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1.1.3 Molecular subtypes 
Human breast tumors are very heterogenous in terms of their pathological and 
molecular profiles, and their clinical response to the therapy. In breast tumors, we 
could not observe one dominant pathway on the formation of tumorigenesis unlike 
colon cancer or pancreatic cancer. Also histological presentation of breast cancer is 
very diverse. Human breast tumors can be classified histologically into 18 subtypes 
at the time of diagnosis. Although this tumor classification helps physicians for 
prognostic evaluation of the patients, there is still quite variation in response to 
therapy (Stingl and Caldas, 2007).   
Human breast tumors have been classified in terms of their gene expression profiling 
by microarray analysis (Perou et al., 2000). According to their gene expression 
patterns, breast tumors could be categorized into five molecular subtypes: Luminal 
A, Luminal B, ERBB2 (HER2), basal, and normal-like. These subtypes reflect the 
gene-expression patterns of the two principal epithelial-cell types in the normal adult 
breast: the luminal epithelial cells and myoepithelial cells. Luminal tumors are ER+ 
positive tumors. They express ER responsive genes and other genes that encode 
characteristic proteins of luminal epithelial cells like PR, GATA3, BCL-2, and the 
luminal cytokeratins CK8 and CK18. The HER2+, normal breast-like and basal-like 
subtypes are predominantly ER-negative. A subset of ER-positive and HER2-
positive tumors cluster with the luminal B subtype. HER2+ tumors express high 
levels of genes located in the HER2 amplicon on chromosome 17q21, including 
HER2 and growth factor receptor-bound protein 7 (GRB7). Normal breast-like 
tumors express non-epithelial genes and genes in the basal cluster. Basal-like tumors 
are largely ER-, PR- and HER2-negative (triple negative) and express genes 
characteristic of basal epithelial cells and normal breast myoepithelial cells, 
including the basal cytokeratins CK5 and CK17. Importantly, later studies associated 
these breast-cancer subtypes with distinct clinical outcomes (Sorlie T et al., 2001; 
Sotiriou C et al., 2003). In Sorlie’s study, they found significant difference in overall 
and relapse- free survival between tumor subtypes. While ER+ Luminal A subtype 
has most favorable prognosis, ER-, HER2+ and basal-like subtypes are associated 
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with shortest and relapse-free survival. Sotiriou’s result provided supporting 
evidence for the previous studies. Moreover they found that ER status is a better 
discriminatory factor for tumor subtypes instead of other clinical features and tumor 
grade.  These findings suggest that ER biology plays pivotal role in breast 
tumorigenesis and final configuration of breast cancer.  
 
1.1.4 Breast cancer stem cells 
Unlike other organs, human mammary gland undergoes many structural changes 
throughout adult life. In humans, before birth mammary fat pad is already invaded by 
branching network of ducts. Ducts are mainly composed of myoepitelial cells and 
specialized luminal layer of epithelial cells. During puberty, with hormonal 
stimulation ductal side branching occurs. Extensive proliferation and terminal 
differentiation is achieved during pregnancy and lactation by formation of lobulo-
aciner structures which contain milk-secreting alveolar cells. After cessation of 
lactation, apoptosis and tissue remodeling convert mammary gland to pre-pregnancy 
state. In order to achieve this kind of great plasticity, mammary gland must contain 
stem cells or early progenitor cells that have ability to differentiate and proliferate. It 
has been proposed that stem cells may be potential targets for malignant 
transformation (Reya et al., 2001). It is hypothesized that normal stem cells and 
cancer cells share many similar characteristics like self renewal capacity and 
differentiation ability.  When mutations are accumulated in cancer stem cells their 
functions could be distrupt and ultimately resulting with self-renewal deregulation, 
tumorigenesis and aberrant differentiation which generates cellular heterogeneity 
found in tumors. Cancer stem cells were first demonstrated in hematological 
malignancies (Bonnet and Dick, 1997) and  later, in solid tumors of breast, brain, 
lung, colon, pancreas, prostate (Al-Hajj et al, 2003; Prince et al., 2007; Eramo et al., 
2008; Dalerba et al., 2007; Li et al., 2007; Ceder et al., 2008).  Al-Hajj and 
colleagues identified that a small population of breast cancer cells had ability to form 
tumor in NOD/SCID mice. These cells were identified by surface markers 
(CD44
+
/CD24
-/low
Lineage
-
). They also noticed that tumors formed in mice share 
same phenotypical heterogeneity with the initial tumor. Therefore CD44 
+ 
CD24
–/low 
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lin
–
 population shows cancer stem cell characteristics like self renewal, 
differentiation and tumorigenic potential. It appers that CD44 is a shared stem cell 
marker and common to different organs and pathologies. But probably CD44
+
CD24
–
/low
Lin
–
 phenotype is tissue-restricted. For example, in pancreatic tumors, a stem cell 
population with the CD44
+
CD24
–/low 
Lin
+
 phenotype was isolated.  
Human mammary tumor-initiating cells isolated from patients express 
EpCAM
+
CD44
+
CD24
-/low
 phenotype.  CD24 is expressed only by human luminal 
epithelial cells, like MUC1. No expression of CD24 in tumor initiating cells indicate 
that these cells are located in basal epithelium (Stingl et al., 2007) 
 
1.1.5 Experimental creation of breast cancer 
To understand molecular pathways involved in breast cancer development mouse 
models have been used in many studies. In early studies chemical carcinogens were 
used in these models to induce breast cancer. Different genes expressed under either 
the MMTV (mouse mammary tumor virus) or the WAP (whey acidic protein) 
promoter was preferred in later studies for the same purpose.  These are viral 
proteins, such as SV40 large T, polyoma virus T antigen or cellular proteins such as 
c-Myc, ErbB2/neu, cyclin D1, cyclin E, ERs, mutant p53, c-Ha-ras, and Wnt-1. 
Current studies generally examine function of cell cycle proteins or tumor 
suppressors by knockout model. Recent findings indicate important role of cyclin D1 
overexpression in a subset of human breast cancers. Altogether some oncogenes and 
pathways are described in mammary gland tumorigenesis, including p53, pRb, 
BRCA1/2, cyclins, CDKs, ErbB2, c-Myc, Wnt-1, ER, and progesterone receptor. 
Another important finding is that these proteins or pathways seem to target different 
cell types or progenitors during tumorigenesis. It has been reported that expression of 
Wnt1 proto-oncogene in transgenic mice generated tumor and this tumor expresses 
progenitor cell markers and contains both luminal and myoepithelial cells. On the 
other hand, mammary tumors from transgenic mice expressing Neu, H-Ras, or 
polyoma T antigen are lacking progenitor cell marker expression and contain only 
myoepithelial cells (Li et al., 2003; Dimri et al., 2005). 
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1.2 Cellular senescence 
1.2.1 Replicative senescence 
Most of the primary cells undergo a limited number of cell division and then they are 
arrested indefinitely in G1 phase of cell cycle. This state is known as replicative 
senescence. It was first demonstrated by Hayflick and Moorhead more than fifty 
years ago. They revealed that normal embryo fibroblasts have limited number of cell 
divisions and then they cease proliferation (Hayflick and Moorhead, 1961). 
Senescence is described as a defense program leading to irreversible cell cycle arrest 
that protects cell when it is exposed to internal and external stress signals (Schmitt et 
al., 2007).  Because of this characteristic of senescence, it is also described as a 
tumor-suppressive mechanism or anti-carcinogenic program (Collado et al., 2007; 
Shay and Roninson, 2004). We now know that replicative senescence is due to three 
main reasons: erosion of telomeres in every round of cell division, accumulation of 
unrepaired DNA and activation of tumor-suppressive pathways, P53 and Rb (Harley 
et al., 1990; Serrano and Blasco, 2007; Ben-Porath and Weinberg, 2004). 
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Figure 3: A variety of intrinsic and extrinsic signals lead to the onset of senescence 
(Ben-Porath and Weinberg, 2004). 
 
Telomers are composed of stretches of repetitive DNA (tandem hexameric repeat 
units-5′-TTAGGG-3′ in vertebrates) and associated proteins that cap the ends of 
linear chromosomes. Telomeric cap protects chromosome from degradation or fusion 
by DNA-repair processes (d’Adda di Fagagna F, 2004). Telomeres are thought to 
end in a large circular structure, called T‑loop. During every S-phase, cells lose 50–
200 base pairs of telomeric DNA because DNA polymerase cannot totally replicate 
DNA ends, called end-replication problem. Human telomeres range from a few kb to 
10–15 kb in length. So it is possible for cells to generate many cell divisions before 
their telomeres are shortened critically to trigger senescence. Cells do not proliferate 
indefinitely mainly because of end-replication problem.  
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Dysfunctional telomere is recognized as a double strand break that activates DNA 
damage response (DDR). DDR activation causes cell-cycle arrest (senescence). 
DNA-damage foci can be detected in senescent cells. These foci contain many DDR 
proteins, such as γ-H2AX, 53BP 1, MDC1, NBS1, MRE11 and RAD17. Also 
senescent cells express  activated protein kinases,  ATM, ATR  and their downstream 
targets CHK1, CHK2 which propagate damage signal to effector molecules such as 
p53 (Herbig U et al.,2004; d’Adda di Fagagna, F. et al. 2003). Telomerase which 
consists of a catalytic protein component (telomerase reverse transcriptase; TERT) 
and a template RNA component can prevent end-replication problem by adding 
DNA repeats to chromosome ends. Normal cells do not express TERT whereas 
germ-line cells and many cancer cells do. In human cells, ectopic TERT expression 
hinder senescence and telomere shortening (Bodnar et al., 1998). But senescence 
triggered by non-telomeric DNA damage or other inducers cannot be prevented by 
telomerase (Chen QM et al., 2001).  
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Figure 4: The DNA-damage response (Campisi and d’Adda di Fagagna, 2007). 
 
1.2.2 Oncogene-induced senescence 
 
Besides telomere dysfunction, senescence can be induced by different types of 
stresses such as oncogene activation. It has been shown that normal cells in culture 
enter senescence in response to the overexpression of the RAS oncogene (Serrano et 
al., 1997) or down-stream effectors RAF, activated MAP kinase and the PML 
oncoprotein (Zhu et al., 1998; Pearson et al., 2000).  Oncogene-induced senescence 
has been suggested as a tumor-suppressive mechanism of cells to prevent them from 
uncontrolled proliferation triggered by abnormal activation of proliferation-driving 
oncogenes (Weinberg and Ben-Porath, 2005). Recently Courtois-Cox et al. propose 
that oncogene-induced senescence might not be the result of hypermitogenic 
signaling, and instead of hyperactivation of RAS pathway, inactivation of it causes 
senescence (Courtois-Cox et al., 2006).  
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Some recent studies presented evidences that DDR might also contribute oncogene-
induced senescence. It is shown that some oncogenes, such as RAS, CDC6, cyclin E, 
and STAT5, induce both senescence and DDR which is triggered by DNA hyper-
replication (Di Micco et al., 2006; Malette et al., 2007). 
 
Nevi, which are benign type of melanocytic tumors, carry activating mutation in the 
BRAF protein kinase. Michaloglou and collaborators showed that human nevi 
present all the characteristics of oncogene-induced senescence, like carrying an 
activated oncogene product (BRAF
E600
), expressing elevated levels of p16
INK4a
 and 
SABG (Senescence associated β-Gal) activity. Additionally, they do not show 
telomere erosion. This and other evidences suggest that oncogene induced 
senescence in nevi present barrier to malignant transformation (Michaloglou et al., 
2005).  
 
In mouse, RAS activation induces senescence through p19
ARF
-p53-p21-Rb pathway 
but in human, mainly through p16
ink4a
-Rb pathway (Serrano et al., 1997). But 
recently Collado and colleagues presented new senescence markers related with 
oncogene-induced senescence by using mouse model (RASV12 knock-in mice) in 
lung adenoma. These are p15
INK4b
, Dec1 and DcR2 (Collado et al., 2005). 
 
1.2.3-Oxidative stress and senescence 
 
Reactive oxygen species (ROS) have shown to be connected with the process of 
senescence and organismal aging (Chen and Ames, 1994; Lee AC, 1999; Lundberg 
and Weinberg, 2000). 
 
ROS are produced by different sources such as mitochondria and membrane bound 
enzymes, NADPH-oxidases. ROS play important physiological roles during cellular 
processes, and their level is strictly regulated by redox homeostasis. At high 
concentrations, ROS are known as toxic by-products of metabolism, and they causes 
damage to lipids, proteins and DNA. Oxidative stress has been connected with 
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several diseases such as cancer, atherosclerosis, pulmonary fibrosis and 
neurodegenerative diseases (Thannical VJ, 2000). On the other hand, at moderate 
concentrations, reactive oxygen species act as signaling molecules in different 
important physiological processes. For example, superoxide and other ROS types 
have been implicated in control of ventilation, erythropoietin production, smooth 
muscle relaxation, as well as involvement in signal transduction and gene expression 
(Droge et al., 2002). Superoxide anion is produced by the reduction of molecular 
oxygen. NADPH oxidase, xanthine oxidase or mitochondrial electron transport 
chains are mainly responsible from superoxide generation. These highly unstable 
superoxides immediately alter to hydrogen peroxide and then to water by catalase or 
glutathione peroxidase. When transition metal ions (ferrous and cuprous ions) 
interact with superoxide and hydrogen peroxide, they modify them to highly reactive 
hydroxyl radical (∙OH). 
 
After the mitochondria, NADPH family of oxidases is the second important 
generator of ROS in mammalian cell.  Neutrophils and macrophages produce high 
amounts of ROS by phagocyte NADPH oxidase (Phox) to combat microbial 
pathogens. Phagocyte NADPH oxidase consists of gp91phox and the regulatory 
subunits p22phox, p47phox, p40phox and p67phox. However, non-phagocytic cells 
contain different types of Nox enzymes, which are homologous to gp91phox and 
generate low level of ROS. NADPH family of oxidases, comprising of five different 
Nox enzymes (Nox1, Nox2, Nox3, Nox4 and Nox5) and two Duox (Duox1 and 
Duox2). These enzymes are localized in the membrane. They all share an amino-
terminal hydrophobic domain, composed of six transmembrane α-helices: the third 
and fifth helices, each containing two histidine residues which accommodate two 
heme binding sites. Carboxyl part of the enzyme holds binding sites for either flavin 
adenine dinucleotide (FAD) and NADPH, which are located in the cytoplasm. 
Alternatively, Nox5 enzymes carry gp91phox core structure and additionally amino-
terminal calcium binding domain (Lambeth et al., 2004).  
 
ROS and senescence association has been studied heavily in different organisms and 
cell types. It has been demonstrated that senescent cells have higher amount of ROS 
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than normal cells (Hagen et al., 1997). Similarly, treatment of primary fibroblasts 
with non-lethal dose of H2O2 causes senescence-like growth arrest (Chen and Ames, 
1994). In Drosophila, overexpression of catalase or superoxide dismutase is result in 
organismal life-span increase (Parkes et al., 1998; Orr and Sohal, 1994). Moreover, 
Nox4 overexpression in NIH3T3 cells results in cellular senescence (Shiose et al., 
2001; Geiszt et al., 2000). 
 
1.2.4 Mechanisms of senescence as a DNA damage response 
 
Many cell types can undergo senescence after DNA damage, which is generated by 
irradiation or treatment with DNA damaging agents. Like telomere-initiated 
senescence, DNA-damage induced senescence depends on p53-p21 pathway 
(DiLeonardo et al., 1994).  Stabilization of p53 after DNA damage probably is 
maintained by ARF (Khan et al., 2004). On the other hand, in many cells, p16 plays 
important role to induce senescence after DNA damage and dysfunctional telomeres. 
It is suggested that DNA damage first inducs p53 and p21 for initial response and 
then p16 which supplies maintenance for senescence state (Ben-Porath and 
Weinberg, 2005).  
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Figure 5: Activation of the senescence program (Ben-Porath and Weinberg, 2005). 
Many chemotherapeutic drugs can induce senescence-like arrest especially the ones 
that affect DNA structure. Such drugs trigger senescence in some tumor cells in 
addition to normal cells and they cause severe DNA damage. Chang et al. showed 
that moderate doses of doxorubicin initiate senescence-like phenotype in tumor cell 
lines (Chang et al., 1999a). In another study, they also observed that drug-induced 
senescence in HCT116 and HT1080 cell lines is declined several fold but not totally 
abolished after inhibition or knockout of p53 or p21 (Chang et al., 1999b). Drug-
induced senescence is observed in tumor cells in vivo as well (Shay and Roninson, 
2004) 
 
1.3 Senescence and immortality in breast epithelial cells 
1.3.1 In vitro senescence mechanisms 
Senescence in normal cells is a very powerful barrier to protect cells from tumor 
development. Human fibroblast and human epithelial cells present some differences 
when they are entering senescence state. Romanov et al. analyzed proliferation 
barriers in human mammary fibroblasts (HMF) and human mammary epithelial cells 
(HMEC) in vitro. They showed that human fibroblast undergo one phase of 
  
37 
proliferation before entering senescence whereas HMECs exhibit two phases of 
proliferation and plateau. They showed that, both HMFs and HMECs go through a 
limited number of divisions before reaching the plateau. In human fibroblast, this 
plateau (phase b) is also termed as Hayflick limit, replicative senescence or M1. In 
HMECs they called M0 or selection. Characteristics of this stage; enlarged size and 
flattened shape, SABG positive staining, low incorporation of BrdU (5-bromo-2-
deoxyuridine) (indication of low proliferation), minimal presence of MCM2 protein, 
2N/4N is >4 and low Annexin-V staining (indication of low death). Compared to 
fibroblast HMEC can overcome from this stage and continue to proliferate ~20-70 
PD (population doublings) before entering second plateau. HMECs that survive from 
first plateau lose expression of p16 protein.  In second stage of growth plateau (called 
M1 or agonescence), HMECs show characteristics of crisis instead of senescence. 
They are heterogeneous in size and morphology, incorporate with BrdU, express 
high levels of MCM2 and 2N/4N is ~1. Also they present high staining with 
Annexin-V, indicating that high proliferation goes with high cell death. 
Chromosomal abnormalities in HMECs are also observed in phase c. When the 
telomere status is analyzed, HMFs and HMECs showed low telomerase activity and 
telomere erosion in similar level. Telomere shortening continued in post-selection 
HMECs at the range of ~3.5kb (55% decrease). Examination of senescence mediator 
proteins showed minimal changes in p53 and p21 protein expression and increase in 
p16 protein level during first growth plateau in HMECs. They observed p53 increase 
during emergence from senescence instead of induction of senescence (phase b) or 
second plateau (phase d). Increase in p14ARF, p21 and decrease in p16 is also seen 
during p53 up-regulation (Figure 7) (Romanov et al., 2001). 
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Figure 6: HMF (human mammary fibroblast) and HMEC (human mammary 
epithelial cells) growth curves (Romanov et al., 2001). 
 
In another study, Stampfer and Yaswen, proposed that first barrier to immortalization 
is driven by Rb pathway respond to accumulated stress in vitro and in vivo. Rb 
inactivation is prevented by increased expression of CKIs. In HMEC, first growth 
arrest is related with elevated levels of p16
INK4A
 and telomere independent. HMECs 
that overcome from fist barrier faces with telomere erosion and genomic instability, 
which leads to telomere-dependent proliferation barrier. If p53 function is absent, 
cell death occurs (termed as crisis). If p53 is functional, viable arrest is observed 
(termed agonescence). They also suggest that to derepress telomerase activity in p16- 
HMEC and to overcome stasis c-myc and ZNF217 amplifications are necessary. 
Conversion to immortalization is achieved after expression of telomerase in HMECs. 
Interestingly they detect telomerase activity just after loss of p53 function (Stampfer 
and Yaswen, 2003).    
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Figure 7: Model for steps in immortalization of cultured HMEC. (Stampfer and 
Yaswen, 2003). 
 
 
1.3.2 Experimental creation of breast cancer cells 
 
Great percentage of human breast cancer emerges from epithelial cells and they carry 
combination of mutations that control cell proliferation and survival. To understand 
the nature of biochemical alterations that leads to transformation of normal cells to 
tumor cells researchers tried to create carcinoma cells from immortalized HMEC by 
introducing cancer-associated genes. Recently Weinberg and colleagues established a 
multistep model for conversion of primary HMEC into tumorigenic state (Figure 8) 
as reviewed in Dimri et al., 2005. They serially introduced three genes, SV40 large-T 
antigen, hTERT and H-Ras oncoprotein into primary HMECs, which already 
bypassed initial M0 growth arrest. Tumorigenicity was determined by ability of 
tumor formation in nude mice by injecting cells subcutaneously and by anchorage-
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independent growth in soft agar by forming colonies. It was shown that introduction 
of the large T antigen, which inactivates p53 and pRb to abolish senescence, 
activates hTERT to promote immortalization and oncogenic H-ras to provide 
constitutive mitogenic signaling. They also associated HMEC transformation with 
amplification of c-myc and ras oncogene expression level. By this method, when 
injected into nude mice, transformed HMEC generates poorly differentiated 
carcinoma (Elenbaas et al., 2006). Also it is shown that SV40 small t, which inhibits 
protein phosphatase 2A, has an important role in transformation of HMEC (Hahn 
WC et al., 2002). Other studies, which analyze role of small-t, showed that small-t 
activates PI3K pathway and active version of Akt1 and Rac1, which are downstream 
targets of PI3K, can substitute small-t function during transformation process (Zhao 
et al., 2003). Raf and Ral-GEF pathways are also implicated in epithelial 
transformation process in a cell type-specific manner (Dimri et al., 2005). Another 
recent study showed the importance of Bmi1. They achieved tumorigenic 
transformation of MCF10A, non-transformed, immortalized cell line, by co-
overexpresion of Bmi1 and H-Ras (Datta S et al., 2007). All these studies show that 
interruption of several cellular pathways could cause tumorigenic transformation in 
human cells.  
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Figure 8: Transformation of HMEC (Dimri et al., 2005). 
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CHAPTER 2.       OBJECTIVES AND RATIONALE 
 
Breast cancer is the most common malignancy and despite the improvements of 
diagnosis and therapies still second leading cause of death among women.  
Breast cancer is a heterogeneous disease in terms of histopathological and molecular 
features. Human breast tumors can be classified histologically into 18 subtypes at the 
time of diagnosis. Moreover, clinical response of patients to breast cancer therapies 
varies among the patients (Stingl and Caldas, 2007). Therefore, there is a great need 
for better understanding of molecular nature and tumorigenesis of disease. 
    
Normal mammalian somatic cells have finite replicative potential in culture 
(Hayflick and Moorhead, 1961). After certain number of doublings, they cease to 
proliferate and undergo some biochemical and morphological changes which is 
referred as senescence. On the other hand, cancer cells have limitless replicative 
potential (Hanahan-Weinberg, 2000). In contrast to this general concept, our group 
observed that some of the Hepatocellular carcinoma-derived and breast cancer-
derived cell lines enter senescence spontaneously (Ozturk N et al., 2006). 
Senescence has been suggested as a barrier against tumorigenesis and proposed as a 
potent anticarcinogenic program (Reddel, 2000). For these reasons, we believed that 
characterization of this observed senescence phenotype and clarification of the 
mechanism serve great importance for generation of possible therapies related with 
induction of senescence in breast cancer.  
 
In the beginning of our studies, a panel of breast cancer cell lines was screened by 
using low-density clonogenic assay and SABG (senescence associated β-gal) 
methods. We found that only 5 out of 12 breast cancer cell lines showed senescence 
phenotype in different percentage. More interestingly, breast cancer cell lines, which 
display senescence, produce heterogeneously positive SABG colonies. These results 
lead us to hypothesize that generation of senescent progeny that we observed in a 
group of breast cancer cell lines could be the result of their stem cell capacity and 
differentiation ability.  
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Therefore our aims in this study were: 
To characterize senescence phenotype and its relationship with their stem cell and 
differentiation capacity; and to characterize the mechanism underlying this 
phenomenon 
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CHAPTER 3.      MATERIALS AND METHODS 
 
3.1. MATERIALS 
 
 3.1.1. Reagents 
All laboratory chemicals were biotechnology grade from Sigma (St. Louis, MO, 
U.S.A), Farmitalia Carlo Erba (Milano, Italy), Merck (Schucdarf, Germany) and 
Amresco (Ohio, USA). Agarose was obtained from Prona (EU). 
 
3.1.2. Oligonucleotides 
Oligonucleotides used in polymerase chain reaction (PCR) were synthesized by 
IONTEK (Istanbul, Turkey). 
 
3.1.3. Primary antibodies 
The following antibodies were used: anti-CD44 (559046; BD Pharmingen), anti-
CD24 (sc53660; Santa Cruz,), anti-ASMA (ab7817; Abcam), anti-CK19 (sc6278; 
Santa Cruz,), anti-p21
Cip1
 (OP64; Calbiochem), anti-p16
Ink4a
 (NA29, Calbiochem), 
and anti-ERα (sc8002; Santa Cruz). 
 
3.1.4. Antibiotics 
Geneticin-(G418 Sulfate) 500 mg/ml solution in double-distilled water. Sterilized by 
filtration and stored at -20°C (stock solution). 500 µg/ml (working solution for stable 
cell line selection), and 250 µg/ml (working solution for maintenance of stable cell 
lines). 
 
3.1.5. Oxidative Stress Detection Reagents 
2′-7′-dichlorodihydrofluorescein diacetate (DCFH-DA) was from Sigma, 
Taufkircher, Germany. 
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3.1.6. Preparation of charcoal treated FCS: 
100 ml FCS (Fetal calf serum) was heat inactivated at 56C for 30 min. Then 
20mg/ml charcoal were added FCS and incubated overnight at cold room with 
stirring. After incubation FCS was centrifuged in Beckman ultrasantrifuj at 20,000 
rpm for 20 min. Charcoal incubation was repeated for 8 hours and then santrifuj 
again in the same conditions. Later FCS was filtered twice. Before using in cell 
culture filtration was repeated under the hood. 
 
 
3.2. SOLUTIONS AND MEDIA 
 
 
3.2.1. General Solutions 
 
 
50X Tris-acetic acid-EDTA (TAE):   2M Tris-acetate, 50mM EDTA             
pH 8.5. Diluted to 1x for working 
solution  
                                                                            
Ethidium bromide: 10 mg/ml in water (stock solution), 30 
ng/ml (working solution) 
 
                                                                           
 
1X Gel loading buffer:                                             
0.25% bromophenol blue, 0.25% xylene 
cyanol, 50% glycerol, 1mM EDTA 
 
Bradford Stock Solution      4.75 ml of 95 % ethanol, 10 ml of 85% 
phosphoric acid , 17.5 mg Coomassie 
Brilliant Blue. Stored in dark at 4°C. 
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Bradford Working Solution 21.25 ml double distilled water, 0.75 ml 
of 95% ethanol, 1.5 ml of 85% 
phosphoric acid 1.5 ml of Bradford stock 
solution. Filtered through Whatman No.1 
paper and prepared freshly. 
 
                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                        
3.2.2. Tissue culture solutions 
 
DMEM/RPMI working medium                              10% FBS, 1% penicillin/streptomycin, 
1% Non-Essential Amino Acid were 
added and stored at 4oC. 
 
                                                                                                                                                                   
 
10X Phosphate-buffered saline (PBS) Per liter: 80 g NaCl, 2 g KCl, 14.4 g 
Na2HPO4, 2.4 g KH2PO4, pH 7.4 
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3.2.3. SDS-PAGE Solutions 
30% Acrylamide mix (1:29)    Per 100 ml: 29 g acrylamide, 1 g 
bisacrylamide in double-distilled water, 
filtered, degassed, and stored at 4°C 
(stock solution). 
5X SDS gel-loading buffer: 3.8 ml double-distilled water, 1 ml of 0.5 
M Tris-HCl, 0.8 ml glycerol, 1.6 ml of 
10% SDS, o.4 ml of 0.05% 
bromophenol-blue. Before use, β-
mercaptoethanol was added to final 
concentration of 5% to reach 1% when 
mixed with protein samples. 
 
5X SDS-electrophoresis buffer   Per liter: 15.1 g Tris base, 95 g Glycine, 
5 g SDS. Diluted to 1X for working 
solution. Store up to 1 month at 4°C. 
                                                                            
10% Ammonium persulfate (APS) 0.1 g/ml solution in double distilled 
water. (Prepared freshly). 
1.5 M Tris-HCl, pH 8.8 : 54.45 g Tris base (18.15 g/100 ml) ~150 
ml distilled water Adjust to pH 8.8 with 
1N HCl. Completed to 300 ml with 
distelled water and stored at 4° C. 
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1 M Tris-HCl, pH 6.8: 12.14 g Tris base ~ 60 ml distilled water 
Adjust to pH 6.8 with 1 N HCl. 
Completed to 100 ml with 
distilled water and store at 4° C. 
 
                                                                                                                                                           
 
                                                                                                                                                                                                     
3.2.4. Immunoblotting solutions 
 
Semi-dry transfer buffer Per liter: 48 mM Tris-base, 39 mM 
glycine, 0.037% SDS, 20% methanol. 
                                                                             
310X Tris-buffer saline (TBS) Per liter: 100 mM Tris-base, 1.5 M 
NaCl, pH 7.6 in double distilled water. 
                                                                               
TBS-Tween (TBS-T) 0.1-0.5% Tween-20 solution in TBS. 
(Prepared freshly) 
                                                                               
Blocking solution 3-5% (w/v) non-fat milk, 0.1-0.5% 
Tween-20 in TBS. (Prepared freshly). 
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3.2.5. RNA Study Solutions 
DEPC-treated water   0.1% Diethylpyrocarbonate (DEPC) 
(v/v) in double-distilled water was stirred 
in loosely plugged bottle. Then 
autoclaved and stored at room 
temperature.                                                                                                                                                                                                                                    
 
 
3.2.6. Immunofluorescence solutions 
H33258 fluorochrome dye 1 mg/ml solution in double-distilled 
water and stored at -20 °C. 
Working solution was 1 µg/ml. 
                                                                                                                                                           
DAPI (4', 6-diamidino-2-phenylindole) 0.1-1 µg/ml (working solution in PBS). 
 
4% paraformaldehyde 4 g paraformaldehyde, in 100 ml. PBS, 
Stir 4 hours at 58°C, pH 7.4. Stable at 
4°C for a week.                                                                                                                                                        
Permeabization solution 100µl TritonX-100 in 100 ml PBS 
BSA (Bovine serum albumin)        3% BSA in 1 X PBS (3 g in 100 ml). 
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3.2.7. Oxidative Stress Reagents 
DCFH-DA Solution 10 mM HEPES (pH 7.5), 10 mM 
glucose, and 1 μM DCFH-DA (dissolved 
in methanol) in 1X PBS. Prepared 
freshly.                                                                                                                                                                                                                              
 
3.2.8. Estradiol, Tamoxifen and Retinoic acid Solutions  
All-trans-retinoic acid (tRA), 17-β-estradiol (E2) and 4-hydroxy tamoxifen (4-OHT) 
were purchased from Sigma.  
tRA was dissolved in DMSO as 10 mM stock solutions, E2 and 4-OHT was 
dissolved in ethanol as 1 mM stock solutions. All stock solutions were stored and 
protected from light at -20°C.  
                                         
 
 
 
3.3. Equipment 
Spectrophotometer           Nano Drop ND-1000 
Horizontal electrophoresis apparatus E-C Thermo Apparatus Corporation  
Power supplies Power-PAC200 and 300, Bio Rad 
PCR machine Techne, TC-512 
Mini vertical gel system Thermo EC120 
Semi-dry transfer cell Bio-Rad 
Transilluminator Vilber Lourmat, program Chemi-capt 
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Inverted light microscope, Axiovert 25 Zeiss                         
Flourescent microscope, AxioCam MRc5 Zeiss, Axiovision Rel 4.6 
 
Hood Holten 
 
CO2 Incubator Holten cell house 
                                                                                                                                                                                                                                                                                                                                                                                                                                             
3.4. METHODS 
 
3.4.1. Tissue Culture Studies 
 
3.4.1.1. Cell lines and Growth conditions of cells: 
Breast cancer-derived cell lines (T-47-D, BT-474, MCF 7, BT-20, MDA-MB-453, 
CAMA-1, SK-BR-3, MDA-MB-157, ZR-75-1, MDA-MB-468, MDA-MB-231 and 
HCC-1937; all from ATCC) were used in this study. T-47-D, BT-474, MCF-7, BT-
20, MDA-MB-468, MDA-MB-453, MDA-MB-231, were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FCS and 50 mg/ml 
penicillin-streptomycin. CAMA-1 and MDA-MB-157 were cultivated in DMEM 
supplemented with 10% FCS, 50 mg/ml penicillin-streptomycin and 1% sodium 
pyruvate. ZR-75-1 and SK-BR-3 were cultivated in RPMI (glucose rich; 4.5g/L) 
medium (Sigma) and McCoy (Biochrom) medium accordingly, supplemented with 
10% FCS and 50 mg/ml penicillin-streptomycin. 
 
3.4.1.2. Thawing cell lines: 
One vial of the frozen cell line from the liquid nitrogen tank was taken and 
immediately put into ice. The vial was left 1 minute on the bench to allow excess 
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nitrogen to evaporate and then placed into 37
o
C water bath until the external part of 
the cell solution was thawed (takes approximately 1-2 minutes). The cells were 
resuspended gently using a pipette and transferred immediately into a 15 ml. sterile 
tube containing 10 ml cold fresh medium. The cells were centrifuged at 1500 rpm at 
4
o
C for 5 minutes. Supernatant was discarded and the pellet was resuspended in 10 
ml 37
o
C culture medium to be plated into 100 mm dish. After overnight incubation in 
a humidified incubator at 37°C supplied with 5% CO2, culture mediums were 
replenished. 
 
 
3.4.1.3. Subculturing of cells  
The cells were passaged when they reached 80-90% confluence. The growth medium 
was aspirated and the cells were washed three times with 1x Phosphate buffer saline 
(PBS). Enough trypsin to cover the surface of the cells was added to the plate and 
waited 1-5 minutes until the cells are detached. The fresh medium was added and the 
suspension was pipetted gently to disperse the cells. The cells were transferred to 
either fresh petri dishes or fresh flasks using different dilutions (from 1:2 to 1:10) 
depending on requirements. All media and solutions used for culture were kept at 
4°C (except stock solutions) and warmed to 37°C before use. 
 
3.4.1.4. Cryopreservation of cell lines: 
For cryopreservation cells should be in exponentially growing phase. 4x106cells/ml 
concentration of cells could be freezed in 1 ml of freezing medium. Cells were 
trypsinized and neutralized with growth medium. The cells were counted and 
precipitated at 1500 rpm for 5 min. The pellet was suspended in a freezing medium. 
Freezing medium: 10% DMSO, 10% FCS and 80% growth medium.1 ml of this 
solution was placed into 1 ml screw capped-cryotubes. The tubes were placed to -
20°C immediately, and kept 2 hours at this temperature. Then tubes were moved to -
80 °C and kept overnight.  The next day, the tubes were transferred into the liquid 
nitrogen storage tank. 
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3.4.2. Protein studies 
3.4.2.1. Protein extraction from cultured cells 
Cells were grown to 70-80% confluency and washed with cold PBS three times. 
Then cells were scraped in cold PBS and centrifuged at 1500 rpm for 5 min at 4 °C. 
Cell pellet could be kept at -80°C or lysed immediately for the experiment. NP-40 
lysis buffer were used to cell lysis. 
  
 
NP-40 (Nonidet P-40) lysis buffer: 50µl 1M Tris pH=8.0 
 125µl 2M NaCl 
 10µl NP-40 (Igepal ca-630) 
 40µl 25X protease inhibitor 
 775 µl ddH2O 
                                                                                                                                
For lysis, the pellet was suspended and incubated in ice for 30 minutes in 4-5 volume 
of NP-40 lysis buffer. The lysate was centrifuged at 13.000 rpm for 30 minutes at 
4°C. Supernatant was taken a new tube. After protein quantification, aliquots were 
stored at -80°C. 
 
3.4.2.2. Bradford Assay for Protein Quantification  
 
Standard curve for protein quantification 
 
Tubes 1 
blank 
2 3 4 5 6 7 8 
BSA (µl) 0 2.5 5 7.5 10 12.5 15 20 
dH2O (µl) 100 97.5 95 92.5 90 87.5 85 80 
Bradford(µl) 900 900 900 900 900 900 900 900 
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Protein sample preparation 
 
Tubes 1 blank 2 3 4 5 6 
Sample(µl) 0 2 2 2 2 2 
dH2O(µl) 98 98 98 98 98 98 
Bradford(µl) 900 900 900 900 900 900 
Lysis 
buffer(µl) 
2 - - - - - 
 
SDS-polyacrlyamide gel for proteins 
 
Acrlyamide concentration (%) Linear range of separation (kD) 
15 12-43 
10 16-68 
7.5 36-94 
5 57-12 
 
10% Resolving gel for SDS-Polyacrlyamide gel electrophoresis 
 
 
Solution 
components 
5 ml 10 ml 15 ml 20 ml 25 ml 30 ml 40 ml 50 ml 
dH2O 2.6 5.3 7.9 10.6 13.2 15.9 21.2 26.5 
30% 
Acrlyamide 
mix 
1.0 2.0 3.0 4.0 5.0 6.0 8.0 10.0 
1.5M Tris (pH 
8.8) 
1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5 
10% SDS 0.05 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
10% APS 0.05 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
Temed 0.004 0.008 0.012 0.016 0.020 0.024 0.032 0.040 
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3.4.2.3. Immunoblot analyses 
 
Cell pellets were incubated in NP-40 lyses buffer (50 mM Tris–HCl, pH 8.0, 250 
mM NaCl, 0.1% Nonidet P-40 and 1Xprotease inhibitor cocktail (Roche) for 30 
minutes in a cold room. Then cell lysates were cleared by centrifugation. Bradford 
assay was performed to quantify the protein concentration of the cell lysates. 30 μg 
of protein was denatured and resolved by SDS-PAGE using 10% or 12% gels. Then, 
proteins were transferred to the PVDF or nitrocellulose membranes. Membranes 
were treated for 1h with blocking solution (TBS containing 0.1% Tween-20 and 5% 
non-fat milk powder) and probed with primary antibody for 1hour. Next, membranes 
were washed three times with TBS-T and incubated with HRP conjugated secondary 
antibody for 1hour. Then, immunocomplexes were detected by ECL-plus 
(Amersham) kit on the membrane. α-tubulin was used as an internal control. 
 
 
3.4.3. RNA studies 
3.4.3.1. RNA extraction and cDNA synthesis 
Total RNAs were extracted from cultured cells with NucleoSpin RNA II Kit (MN 
Macherey-Nagel, Duren, Germany) according to the manufacturer’s protocol. Two 
micrograms of total RNA were reverse-transcribe into cDNA in a total volume of 20 
µl using RevertAid First Strand cDNA synthesis kit (MBI Fermentas, Vilnius, 
Lithuania).  
 
3.4.3.2. RT-PCR and Real-time PCR analysis 
The PCR reactions were usually carried out with 1µl of cDNA, using the appropriate 
number of cycles and annealing temperature (Tm) provided in Table1.  PCR products 
were analyzed on a 2% agarose gel and visualized with ethidium bromide under UV 
transillumination. 
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BioRad iCycler system was used to analyze Nox2 and Nox5 genes expression in 
breast cancer cell lines. Reactions were performed in a 20 µl volume with 2 µl of 
1/3-diluted template cDNA, 10 pmol of forward and reverse primers, and 10 µl 
DyNAmo HS SYBR Green qPCR mix (Finnzymes). Same primer pairs for Nox2 and 
Nox5 were used for real-time PCR analysis, as listed in Table1. PCRs were 
incubated for 5 min 95°C, followed by 45 amplification cycles with 30 sec 
denaturation at 95°C, 30 sec annealing at 60°C, 30 sec extension at 72°C. Samples 
were analyzed in triplicate, and product purity was checked through dissociation 
curves at the end of real-time PCR cycles. Standard curve for each primer pair was 
performed by using five serial dilution points (2-fold dilutions) of a selected cell line 
cDNA. Primer amplification efficiency was calculated by using the formula;  
E=2
[-1/slope]
. Real time RT-PCR results were evaluated by using 2
-ΔΔct 
method (Pfaffl, 
2001), with a brief modification on the formula. The expression changes were 
calculated and compared as “Arbitrary Unit”s. The modified formula used was;  
 
Arbitrary unit= [(ETarget gene)
 ΔCtTest(referance-sample)
/ (EActin)
ΔCtActin(referance-sample)
]*1000 
 
“Sample” represents breast cancer cell lines while “reference” represents ct value of 
negative controls. Because comparisons were performed between breast cancer cell 
lines and no exact control exists for each cell line we decided to use ct value of our 
negative control as a reference value. β-Actin was used as an housekeeping gene in 
the study. 
 
 
3.4.4. Low-density clonogenic assay 
Cells (20–60/cm2 in 100mm plates or 150-200/cm2 onto coverslips in six-well plates) 
were plated and grown 1–3 weeks to obtain isolated colonies formed with 100–1,000 
cells. The medium was changed every 4 days, and colonies were subjected to SABG 
(Senescence associated β-galactosidase) staining. 
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3.4.5. SABG (Senescence associated β-galactosidase) assay 
SABG activity was detected by using a described protocol (Dimri GP. et al., 1995). 
After eosin or nuclear fast red counterstaining, SABG positive cells were manually 
counted. 
 
 
3.4.6. SABG and BrDU (Bromo deoxyuridine) incorporation assay co-staining 
Sub-confluent cells were labeled with BrdU (10µg/ml) for 24 hour in freshly added 
culture medium. After BrDU labeling, SABG staining procedure was followed. 
BrDU assay was continued with 70% ice-cold methanol fixation for 10 min and then 
DNA denaturation in 2N HCl for 20 min. After cells were incubated with anti-BrdU 
antibody (Dako), the following steps were carried out with the DakoCytomation 
Strepavidin-HRP and Liquid DAP+Substrate chromogen system (Dako, CA, 
U.S.A.), according to the supplier’s instructions.  
 
3.4.7. Retinoic Acid treatment of breast cancer cell lines 
Cells were seeded as low density (1500 cells/well) onto the coverslipts in six-well 
plates as duplicate. One day after seeding, 100 nM tRA (trans-Retinoic acid) 
treatments were started. Control plates were received only carrier which was DMSO. 
Every 2 days tRA and carrier was replaced. After 10 days experiment was stopped 
and plates were subjected to SABG staining. Then cells were stained with eosin as a 
counterstaining and mounted onto the slayts. SABG positive cells were counted 
manually under the light microscope in 4 different areas.  
 
3.4.8. NAC (N-acetyl-L-cysteine) treatment 
Cells were plated in low density (1000 cells/well) into six-well plates with normal 
medium. 48 hours later, experiment were started by removing the initial medium and 
followed by adding fresh medium supplemented with 10 mM NAC. Negative 
controls were carried out in medium supplemented with only ddH2O. Experiment 
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was continued until each colony reached 400-500 cells. NAC supplemented medium 
was removed 24 hour before SABG assay was performed.  
 
3.4.9. Co-staining with DCFH-DA (2′-7′-dichlorodihydrofluorescein diacetate) 
and MitoTracker 
Cells were seeded in six-well plates with low density (1000 cells/well). After 
colonies reached 300-400 cells, experiment were started. During this time, NAC 
treatment was carried out previously described protocol. Cells were washed with pre-
warmed PBS for 3 times and incubated with DCFH-DA-MitoTracker reaction 
mixture which is composed of 10 mM HEPES (pH 7.5), 10 mM glucose, 1 µM 
DCFH-DA ve 125 nM MitoTraker in 1X PBS for 20 min at 37°C. Cells were washed 
3 times with pre-warmed PBS again and analyzed under fluorescent microscope. 
 
3.4.10. NBT (Nitro Blue Tetrazolium) assay 
Cells were plated in 35 mm plates. Sub-confluent cells were washed with pre-
warmed PBS for 3 times. Cells were incubated NBT (1.6 mg/ml) in 1xPBS for 45 
min at 37°C. Then color change was observed under bright field microscope. Then 
experiment was continued with SABG assay. 
 
 
3.4.11. Low density clonogenic assays and immunohistochemistry 
Cells were seeded as low-density on coverslips in six-well plates (500-2000 cells, 
according to plating efficiency) allowed to grow in DMEM supplemented with 10% 
fetal calf serum, with medium change every three days, until they formed colonies of 
a few hundred cells. Depending on cell lines, this took one to two weeks. For BrdU 
assays, cells were labeled for 24hour prior to immunocytochemistry. For simple 
immunoperoxidase assays, cells were fixed with cold methanol for five minutes, and 
then blocked with 10% FCS in PBS for 1h at room temperature. This was followed 
by incubation with primary antibody for 1h. Cells were then washed with PBS three 
times and subjected to immunostaining using the Dako-Envision-dual-link system 
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and the Liquid DAP Substrate chromogen system (Dako, CA, USA), according to the 
manufacturer’s instructions. Hematoxylin was used as a counter-stain when the 
visualization of cells was necessary. For SABG-immunoperoxidase co-staining 
studies, unfixed cells were first subjected to SABG assay, and then fixed prior to 
immunostaining assays. Hematoxylin counter-staining was omitted for co-staining 
experiments, unless cells were negative for SABG staining. 
 
 
 
 
Table 1: Antibodies used in this study 
 Antibody 
Stem cell/progenitor marker CD44 
Luminal marker CD24, ER and CK19 
Myoepithelial marker ASMA 
 
 
3.4.12. Estrogen and tamoxifen treatment 
Cells were seeded under low-density clonogenic conditions onto coverslips in six-
well plates and then cultivated in standard culture medium for seven to eight days. 
Then, cells were fed with phenol red-free DMEM (Gibco) supplemented with 5% 
charcoal-stripped fetal calf serum for 48hour, followed by two successive 48h 
treatments with 10
-9M E2 (17β-estradiol; Sigma), 10-6-10-9M 4-OHT (4-
Hydroxytamoxifen; Sigma) or an ethanol vehicle, under the same conditions. 
Colonies were then subjected to SABG assay. Each experimental condition was 
conducted in triplicate and experiments were repeated three times. 
 
3.4.13. Generation of estrogen receptor-overexpressing clones 
T47D-iso23 cells were transfected with the expression vector pCMV- ERα (Al-
Otaibi et al., 2006) or an empty vector using FuGENE-6 (Roche). ER overexpressing 
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and control clones were selected with 500μg/ml G418 for three weeks. Isolated 
single-cell-derived colonies were picked and expanded in the presence of G418. 
 
3.4.15. Lentiviral infection and generation of p21Cip1 knock-down clones 
We used mission shRNA plasmid pLKO.1<-puro-p21 (NM_000389.2-640s1c1, 
Sigma) for p21cip1 knock-down. Control vector shRNA-pGIPz-SCR-puro and 
helper packaging mix (Invitrogen) were also used. HEK293T co-transfected with the 
appropriate vector and packaging mix, using CalPhos Mammalian Transfection Kit 
(Clontech), was following the manufacturer's instructions. After 48hour of culture, 
virus-containing culture media were collected, filtered and used to infect T47D-iso23 
cells. After four hours of infection, stable cells were selected with 1 μg/ml 
puromycin for seven days. 
 
3.4.16. Clinical Samples 
Freshly frozen breast tumor specimens were collected at Ankara Numune Hospital. 
The use of the tissue material was approved by the Research Ethics Committee of 
Ankara Numune Research and Teaching Hospital, and consents were obtained in 
accordance with the Helsinki Declaration. 
 
3.4.17. Nude mice tumorigenicity assays 
For nude mouse xenotransplantation studies, MCF-7, T47D, CAMA-1, BT-20, 
HCC1937 and MDA-MB-453 cell lines were used. 5x10
6 
cells were injected 
subcutaneously into CD-1 “nude” mice (Charles River).  Local tumor growth was 
monitored for 10 weeks at the injection sites. These experiments have been approved 
by the Bilkent University Animal Ethics Committee (Bil-AEC) and this study 
protocol complied with Bilkent University’s guidelines on the humane care and use 
of laboratory animals. 
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3.4.18. Statistical analyses 
Significant differences were evaluated using unpaired Student's t test for compared 
samples sizes of 10 or higher. Otherwise, one-tailed Fisher's exact test was used with 
2 × 2 tables; p < 0.05 was considered statistically significant. On the graphical 
representation of the data, y axis error bars indicate the standard deviation for each 
point on the graph. 
 
 
3.4.19. Cluster analysis 
The two-channel microarray data containing 8102 cDNA genes/clones, generated by 
Sorlie et al. (2003) were downloaded from the Stanford Microarray Database (SMD) 
(http://genomewww. stanford.edu/MicroArray/). In the downloading process, “log 
(base 2) of R/G Normalized Ratio (median)” parameter was used for data filtering. 
We have median-centered expression values for each array. Arrays and genes with 
greater than 75% good data representing the amount of data passing the spot criteria 
were selected. Sixty-eight tissue samples were obtained according to this criterion 
and annotated with the subtypes described by the authors, found in “Supplementary 
Information” of the data set in SMD. The expression values of “500 gene signature,” 
defined by the authors, were extracted from the data. Gene expression profiles of 31 
breast cancer cell lines performed by Charafe-Jauffret et al., (2006) using the whole-
genome cDNA microarray Affymetrix HGU-133 plus 2, was obtained from the 
“Supplementary Table” of the article. The authors filtered genes with low and poorly 
measured expression, and with low expression variation, retaining 15,293 genes. 
After log transformation of the data, we median normalized the arrays of the data in 
R language, using the Bioconductor biostatistical package (www.r-project.org/ and 
www.bioconductor.org/). The “500 gene signature” tumor data (Sorlie et al., 2003) 
and the normalized breast-cancer cell line data (Charafe-Jauffret et al., 2006) were 
combined with respect to probe IDs using a set of customized perl routines (source 
codes are available upon request), as described (Gur-Dedeoglu et al., 2008). A set of 
175 genes was common. “Median center” normalization of genes was made for the 
merged data set for the total samples. We performed unsupervised hierarchical 
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clustering with the 99 samples, including 31 breast cell line (Charafe-Jauffret et al., 
2006) and 68 breast tumor samples (Sorlie et al., 2003) by pair-wise complete-
linkage hierarchical clustering parameter, using the Gene-Pattern program. The 
Pearson correlation method was used for distance measurements. 
Clustering was visualized by java treeview, again using Gene-Pattern 
(http://www.broad.mit.edu/cancer/software/genepattern/). 
 
 
 
Table 2: List of gene-specific primers used for expression analysis of Nox genes 
Genes Primer pairs (upper: forward, lower: reverse) Tm, 
 
Cycle 
Nox1 5’-CATTCATATCCGAGCAGCAG-3’ 
5’-CCAGCACAGCCACTTCATAC-3’ 
60 32 
Nox2 5’-CACACATGCCTTTGAGTGGT-3’ 
5’-GTGCACAGCAAAGTGATTGG-3’ 
60 32 
Nox3 5’-ACTCCCTTCGCTGCTCTTCT-3’ 
5’-CCGGTTTCCAGGGAGAGTA-3’ 
60 32 
Nox4 5’-TCCTCGGTGGAAACTTTTGT-3’ 
5-’TGTCCCATATGAGTTGTTCTGG-3’ 
60 32 
Nox5 5’-CGGTCTTTCGAGTGGTTTGT-3’ 
5’-TGGCCTTCATGTCATTCTTG-3’ 
60 32 
GAPDH 5’-GGCTGAGAACGGGAAGCTTGTCAT-3’ 
5’-CAGCCTTCTCCATGGTGGTGAAGA-3’ 
62 20 
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4.1.1. Classification of breast cancer cell lines as senescent cell progenitor (SCP) 
and immortal cell progenitor (ICP) subtypes 
Using low-density clonogenic assay and SABG staining, a panel of 12 breast cancer-
derived cell lines, consist of luminal (n=7) and basal (n=5) subtypes, were screened 
(Table 3). This screening showed that only 5 out of 12 breast cancer cell lines present 
heterogeneous staining with SABG (Figure 10-11).   
 
In clonogenic assay, cells were seeded in low density and cultured until they perform 
6-10 PD. At the end of the assay each cell create a separate colony, each one has 
several hundred cells. Clonogenic assays are very good methods to detect 
stem/progenitor cells and properties of their progeny (Stingl J, 2009). This analysis 
enables us to classify our breast cancer cell line panel in to two categories according 
to their capacity to produce senescence progeny. First group of breast cancer cell 
lines produce progeny with high percentage of senescence (12-40%) whereas second 
group cannot generate considerable amount senescent cells in the colonies (<5%). 
The first group is named as “senescent cell progenitor” (SCP) subtype (T47D, 
BT474, ZR-75-1, Cama1 and MCF7) and the second group is called “immortal cell 
progenitor” (ICP) subtype (MDA-MB-453, BT20, SK-BR-3, MDA-MB-468, 
HCC1937, MDA-MB-231 and MDA-MB-157) (Figure 12).  
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Figure 10: Representative pictures of SABG staining in breast cancer cell line panel. 
Five cell lines (T47D, BT-474, ZR-75-1, MCF7, and Cama1) show positive SABG 
staining whereas others (MDA-MB-453, BT20, SK-BR-3, MDA-MB-468, 
HCC1937, MDA-MB-231 and MDA-MB-157) present negative SABG staining. 
 
 
 
 
 
Figure 11: SABG staining results of breast cancer cell lines used in this study. 
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Figure 12: SABG index (% SABG positive cells/ colony) of breast cancer cell line 
panel. 
First group of breast cancer cell lines which is named as SCP subtype produce 
progeny with high percentage of senescence (12-40%) whereas second group which 
is called ICP subtype cannot generate considerable amount senescent cells in the 
colonies (<5%). 
 
To test whether the observed senescence phenotype in breast cancer-derived cell 
lines is intrinsic to cell line or due to the presence of side population, isogenic clones 
were generated from two breast cancer cell lines. T-47-D and BT-474 were selected 
to implement single cell cloning. Because previously these cell lines generated 
highest percentage of SABG positive progeny during SABG screening. From T-47-D 
and BT-474, 20 clones and 11 clones were established respectively. They were 
subjected to senescence associated β-galactosidase (SABG) screening. When highest 
percentage of SABG positive result was 61.46% in T-47-D isogenic clones, we can 
only get 52.7 % of SABG positive result in BT-474 isogenic clones (Figure 13). 
Then we choose 6 clones from T-47-D isogenic clones and 4 clones from BT-474 
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isogenic clones among the highest and lowest positive ones. These clones were 
maintained in the culture a long period of time (>60PD), but they did not fully 
entered senescence. Also none of them gained ICP type during this period. Their 
SABG indexes (percentage of SABG positive cells per colony) were remained 
around parental cell line. This result shows that senescence phenotype that is 
observed in breast cancer-derived cell lines is not related with replicative senescence. 
Breast cancer cell line clones (unlike our observation in Huh7 clones) do not enter 
totally senescence, but they maintained their senescent cell population in some 
fluctuated percentage. 
 
 
Figure 13: SABG index of T47D and BT-474 isogenic clones.  
20 isogenic clones from T47D and 11 isogenic clones from BT-474 were established. 
All of the clones were subjected to SABG staining. Most of the clones showed 
similar SABG staining pattern like their parental cell lines.  
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To confirm senescent phenotype in SCP group with another test, long-term (24hour) 
BrdU incorporation assay was performed under mitogenic stimuli (Wei and Sedivy, 
1999). In order to analyze senescence and BrdU correlation we performed co-
staining. For this purpose first, cells were incubated with BrdU for 24 hour, then 
freshly stained with SABG, fixed and subjected to anti-BrdU staining, followed by 
DAB incubation. Under these conditions, senescent cells display blue staining, 
whereas DNA-synthesizing cells have brown nuclear staining. As shown in Figure 
14, in two different cell lines, T-47D and CAMA-1, and clones T47D-iso23 and BT-
474-iso23, SABG-positive blue cells and BrdU-positive brown cells can be 
distinguished by this double-staining method. The same figure also shows that most 
cells are blue or brown, indicating that they are either senescent (SABG+/BrdU-) or 
proliferating (SABG-/BrdU+) in response to mitogenic stimuli. This result indicates 
that SABG positive senescent cells were lost DNA synthesis ability irreversibly in 
this terminal differentiation stage. 
 
 
Figure 14: SABG and BrdU co-staining in Cama1, T47D, T47D-iso23 (isogenic 
clone of T47D) and BT-474-iso23 (isogenic clone of BT-474). 
As seen in the picture, senescent cells presented blue SABG+ staining whereas no 
BrdU staining, indicating that they were not proliferating. 
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4.2. Role of oxidative stress in breast cancer cell senescence 
 
4.2.1. ROS accumulation is related with senescence 
Cellular senescence can be induced by different stimuli. One of them is oxidative 
stress. ROS are by-products of normal cell oxidative processes. ROS play different 
roles in cellular physiological functions like proliferation, apoptosis, differentiation 
and senescence.  
We reasoned that senescence that we observed in breast cancer cell lines can be 
related with ROS accumulation in the cell. Therefore, we decided to co-stain our 
senescence-positive cell line, Cama-1, with oxidant-sensitive dye DCFH-DA and 
MitoTracker to show ROS accumulation. DCFH-DA is an oxidant-sensitive non-
fluorescent dye that gives a fluorescence signal upon oxidation, and MitoTracker is a 
mitochondrion-selective probe that does not fluoresce until it is oxidized. MDA-MB-
468 cell line, which is a senescence-negative cell line, was included to the study in 
order to compare the difference between senescence-positive and senescence-
negative groups.  
All the cells were seeded in low density clonogenic conditions. Cama-1 and MDA-
MB-468 cells were treated with 10 mM NAC in order to prevent ROS accumulation 
in the cells. The media containing fresh NAC was added to the plates every three 
days and only ddH2O was added to the control plates. Half of the experiment was 
stopped at day 10 and other half was finalized at day 13. Then cells were co-stained 
with DCFH-DA and MitoTracker.  
There wasn’t important difference in terms of ROS accumulation in control plates 
compared to the treatment received plates at Day 10 (Figure 15). But interestingly, 
high amount of ROS accumulation was observed at Day 13 in Cama-1 control plates 
compared to NAC treated plates (Figure 16). Importantly, 10 mM NAC treatment in 
Cama-1 cells caused statistically significant decrease in ROS accumulation (Figure 
17). Another observation from this experiment was that there were no significant 
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experiment was that there were no significant changes in MitoTracker staining levels 
in Cama-1 control and treated plates. This result demonstrates that ROS 
accumulation is not of mitochondrial origin. There was also a low level of ROS 
accumulation in MDA-MB-468 cells. But this accumulation was not as significant as 
Cama-1 cells. Another point is there were no significant difference between control 
and treated plates in terms of their ROS accumulations. 
    
 
 
Figure 15: Co-staining with DCFH and Mitotracker in Cama1 and MDA-MB-468 
cell lines at Day 10. No significant ROS accumulation was observed in Cama1 cells. 
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Figure 16: Co-staining with DCFH and Mitotracker in Cama1 and MDA-MB-468 
cell lines at Day 13.  
Increased level of ROS accumulation was observed at Day 13 in Cama-1 control 
cells compared to NAC treated cells. 10 mM NAC treatment in Cama-1 cells caused 
decrease in ROS accumulation. No major difference was seen between control and 
NAC treatment received cells in MDA-MB-468. 
Mitotracker staining didn’t present any significant variation in the plates suggesting 
that ROS accumulation is not originating from mitochondria. 
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Figure 17: Percentage of DCFH positive cells before and after NAC treatment in 
Cama1 and MDA-MB-468 plates at Day13.  
High percentage of Cama1 cells show ROS accumulation compare to MDA-MB-468 
cells. Also after 10mM NAC treatment ROS levels decrease significantly in Cama1 
cells. 
 
4.2.1.1. ROS accumulation was confirmed by co-staining with NBT and SABG 
NBT assay was used to confirm our previous results where we observed ROS 
accumulation in Cama-1 cells.  
 
Reduction of NBT (nitro blue tetrazolium) to formazan is one of the established 
methods to detect intracellular O2¯generation. NBT is reduced by only O2¯, which 
may act as electron donor or acceptor, but not by H2O2, which is an oxidizing agent. 
Moreover, NBT preferentially detects intracellular O2¯ (Berridge et al., 2005).  
 
BT-474 cells were co-stained, which is again a senescence-positive cell line, with 
NBT and SABG (detail of co-staining is described in the methods section). As seen 
in the Figure 18, most of the SABG positive cells co-stained with NBT, and some of 
them stained only with NBT. SABG and NBT did not totally overlap. This can be 
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explained by the scenario that ROS accumulation starts and then ROS may activate 
some signaling pathways and this induces senescence response. 
 
 
Figure 18: Co-staining of BT474 cells with NBT and SABG.  
Most of the SABG positive cells overlapped with NBT stained cells. This 
demonstrates that senescence and ROS increase occurs in these cells at the same 
time. 
 
4.2.2. Relationship between ROS accumulation and senescence 
To understand whether 1) ROS accumulation is related with senescence, and 2) 
inhibition of ROS can reverse senescence phenotype, we decided to treat Cama-1 
cells with NAC. NAC is reduced glutathione (GSH) provider for cells and a 
scavenger of ROS (Staal et al, 1990).  
 
For this experiment Cama-1 cell line, which is one of the breast cancer cell lines 
from our SCP group, was chosen. Cells were seeded in low density and treated with 
10mM NAC (experiment details are in the material-methods section). Only ddH2O 
was added to the control group. One set of experiment was stopped at day 10 and the 
other group was stopped at day 15. Then SABG assay was performed in order to 
check their senescence status. SABG positive cells were counted manually.  
 
At Day 10, decrease in SABG index (percentage of SABG positive cells per colony) 
in either 10 mM or 20 mM NAC treated cells compare to untreated control was 
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observed. Also, similar very low level of SABG index was found at Day 15. But 
untreated control plates showed higher percentage of SABG index compare to day 10 
control plates. This was probably because of the increase in ROS accumulation in 
these cells in the absence of NAC when the duration got increased (Figure 20). These 
results showed that by inhibition of ROS accumulation in Cama1 cells we were able 
to decrease the number of cells that enter senescence stage. This provides evidence 
that there is a relationship between ROS accumulation and senescence phenotype in 
Cama1 cell line, which is a representative of SCP group of breast cancer cell lines. 
 
 
 
Figure 19: SABG staining of Cama1 cells after treatment of NAC.  
NAC treatment protects cells from senescence both Day10 and Day15 
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Figure 20: Quantification of SABG-positive cells in colonies from NAC treated and 
untreated Cama1 cell line.  
Either 10 mM or 20 mM NAC protects cells from ROS accumulation and 
senescence. Also increase in SABG index of day 15 compare to SABG index of day 
10 in untreated control plates could be the indicator of ROS accumulation. 
 
4.2.3. Differential expression of NOX genes in breast cancer cell lines 
Nox family of NAPDH oxidases is a family of enzymes whose physiological 
function is ROS generation. There are five important members of family of NAPDH 
oxidases, Nox1-5.  
 
Previous experiments showed us that ROS accumulation in our senescence-positive 
breast cancer cell lines was from intracellular origin. Therefore, we wanted to 
analyze expression of Nox genes in our breast cancer cell line panel by using RT-
PCR method. As seen in Figure 21, only Nox2 and Nox5 expressions were elevated 
in senescence-positive group of breast cancer cell lines compared to some of the cell 
lines in senescence-negative group. After this RT-PCR result, we wanted to extend 
and confirm our expression studies. Nox2 and Nox5 expression levels were 
evaluated by quantitative real-time PCR (qRT-PCR). qRT-PCR results were  
matched with previous RT-PCR results. qRT-PCR results were calculated as 
arbitrary unit. In Nox2, BT-474, T-47-D and Cama-1 showed increased expression. 
Only T-47-D presented substantial increase in expression compared to other cell 
lines in Nox5 ( 
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Figure 21: Expression analysis of Nox genes in breast cancer cell line panel by RT-
PCR.  
Data showed that expression of Nox2 and Nox5 were increased in senescence 
positive cell lines.  
 
 
Figure 22: Real time PCR analysis of Nox2 and Nox5 expression in breast cancer 
cell lines.  
BT474 showed highest expression of Nox2. In other senescence positive cell lines, 
except MCF7, high level of Nox2 expression was observed. Nox5 expression was 
very striking in T-47-D  
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4.3. Role of P16
INK4a
 and p21
WAF1/Cip1
 in breast cancer senescence 
P21/p53 and P16
INK4a 
/Rb pathways are two crucial pathways implicated in the 
senescence program. The cyclin-dependent kinase inhibitor p21 (also known as 
p21
WAF1/Cip1
) has profound role in cell cycle arrest, differentiation and cellular 
senescence. P21
WAF1/Cip1
 mediates these functions either through p53-dependent or 
independent of the classical p53 tumor suppressor pathway (Abbas T. and Dutta A., 
2009). 
 
4.3.1. P16
INK4a
: No significant correlation between P16
INK4a
 expression and SCP 
phenotype. 
P16
INK4a 
is a tumor suppressor and Cdk inhibitor. P16
INK4a
 blocks pRb 
phosphorylation by inhibiting cdk4 and cdk6 association with cyclin D. Failure in 
pRb phosphorylation and in E2F release cause G1 cell cycle arrest. 
 
Therefore we wanted to examine expression status of p21
Cip1 
and P16
INK4a
 in our 
breast cancer cell line panel. We performed low density cloning assay and 
immunoperoxidase staining to detect p21
Cip1 
and P16
INK4a
 expression in the colony 
basis. Two SCP cell lines displayed heterogeneously positive P16
INK4a
 staining. On 
the other hand three of seven ICP cell lines displayed homogenously positive 
staining (Figure 23). We couldn’t found any statistically significant association with 
P16
INK4a 
expression and SCP subtype (p = 0.6893).  
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Figure 23: No significant correlation between P16INK4a expression and SCP 
phenotype.  
P16
INK4a 
immunoperoxidase staining in breast cancer cell lines panel. From SCP 
subgroup ZR-75-1 and Cama1, from ICP group SK-BR-3 and MDA-MB-468 
showed heterogeneous P16
INK4a 
staining. MDA-MB-157 was full positive for 
P16
INK4a. Results didn’t show any correlation between SCP subgroup and P16INK4a 
expression. 
 
4.3.2. p21
Cip1
 expression correlates with SCP subgroup 
 
p21
Cip1 
analysis showed that 4 out 5 SCP subtypes of cell lines express strong nuclear 
p21
Cip1 
heterogeneously.  ICP subtype breast cancer cell lines were negative for the 
P21
Cip1
expression (Figure 24). The association of p21Cip1 expression with the SCP 
subtype was statistically significant (p =0.0100)  
 
These results suggested that there is a relationship between senescence and P21
Cip1 
expression. But Immunoperoxidase results didn’t provide any correlation related 
with P16
INK4a
 expression and senescence phenotype in our breast cancer panel. 
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Figure 24: p21Cip1 correlate with SCP subgroup. p21
Cip1 
immunoperoxidase staining 
in breast cancer cell lines panel.  
p21
Cip1 
analysis showed except Cama1 the entire SCP group of breast cancer cell 
lines expresses strong nuclear p21
Cip1 
heterogeneously. All ICP subtype breast cancer 
cell lines were negative for the P21
Cip1
expression. The association of p21
Cip1 
expression with the SCP subtype was statistically significant. 
 
 
To confirm relationship between senescence and P21
Cip1, 
SABG and p21
Cip1
 co-
staining was performed in T47D cells. Co-staining showed that SABG positive 
staining mostly overlap with p21
Cip1
 expression in T47D cells. Co-staining also 
carried out MDA-MB-231 cells. As expected MDA-MB-231 cells didn’t showed any 
positive staining for either SABG or p21
Cip1
 (Figure 25).  
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Figure 25: Co-staining of SABG and p21Cip1 in T47D and MDA-MB-231 cell lines.   
In T47D, SABG positive staining mostly overlaps with p21Cip1staining confirming 
that there is a relationship between senescence and p21Cip1. 
 
4.3.3. p21
Cip1
 is partially responsible for senescent cell progenitor phenotype 
 
Strong relationship between p21
Cip1
 and SCP subgroup of cell lines lead us further 
analyze the involvement of p21
Cip1
 in the senescent phenotype of these cell lines. We 
wanted to down-regulate p21
Cip1 
and checked its effect on the senescence.  
 
For this purpose after infection of T47D with lentiviral vectors encoding p21
Cip1
 
shRNA (T47D-p21sh) or a scrambled control (T47D-scr), two clones were 
generated. Western blot was confirmed successful p21
Cip1 
knockdown in T47D-
p21sh cells (Figure 26B).Then we seeded both cell lines in low-density conditions. 
After 10 days, SABG and BrdU staining were performed. But because cells were 
formed tight clusters, it was difficult to evaluate SABG positive cells. For this reason 
we used BrdU staining instead of SABG to determine senescent cells (Figure 26C). 
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Colonies selected randomly and BrdU positive cells were counted manually (Figure 
26D). The T47D-scr cell line generated BrdU+ progeny at a rate of 48±20% per 
colony (n=18). Under the same conditions, T47D-p21sh cells displayed BrdU+ 
progeny at a rate of 65±12% per colony (n=18), with a significant (p = 0.0043) 
increase in the number of cells escaping terminal arrest (Figure 26E).  
 
These results display that p21
Cip1
 was partially responsible for the induction of 
senescence observed in the progeny of T47D cells. 
 
 
 
Figure 26: p21
Cip1
 is partially responsible from senescence arrest in T47D cell line  
A) p21
Cip1 
is downregulated by lentiviral infection of p21
Cip1
 shRNA. Down 
regulation was confirmed by western blot. B) Senescence is assessed by BrdU assay. 
Cells were seeded in low-density condition and cultivated 10 days in cell culture in 
order to generate colonies. Brown color staining represents BrdU incorporated 
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proliferating cells. BrdU incorporation increased in T47D-p21sh cells compare to 
T47D-scr (control) cells. C, D) Colonies selected randomly and cells counted 
manually from BrdU assay. T47D-p21sh cells generated BrdU positive cells at a rate 
of 65±12% per colony. But T47D-scr cells only displayed positive progeny at a rate 
of 48±20% per colony (n=18). 
 
4.4. Role of ER in breast cancer senescence 
 
4.4.1. ER expression and senescence 
P53 pathway is one of the important pathways in cellular senescence. Even though 
p21
Cip1 
is downstream target of p53, our T47D cell line does not express wild-type 
p53 (Table 4). Estrogen effects cell cycle progression through loss of p21
Cip1
 (Cariou 
et al., 2000). E2 mediates p21 inhibition by c-myc (Mukherjee and Conrad, 2005). 
Myc gene is direct target of ER complex (Dubik and Shiu, 1992). Therefore, we 
wanted to check involvement of ER in senescence phenotype in breast cancer cell 
lines. First SABG and ER co-staining was performed in T47D and MDA-MB-231 
cells. Results showed that T47D cells display strong nuclear ER immunoreactivity in 
most of the cells, but some of the cells were ER- (Figure 27). More interestingly, 
These ER- cells were SABG+, referring that the senescence occurred in T47D cells 
as a result of ER lost. In contrast to T47D, MDA-MB-231 cells do not show ER 
expression and SABG negative. Thus, the senescence susceptibility was restricted to 
ER+ T47D cells; however the senescent cells no longer expressed nuclear ER 
protein. 
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Figure 27: ER lost related with senescence phenotype in T47D cells.  
T47D and MDA-MB-231 cells were co-stained with ER and SABG. Heterogenic ER 
expression was observed in T47D cells. Interestingly SABG positive cells were 
negative for ER expression. As expected MDA-MB-231 cells were negative for both 
ER and SABG. 
 
 
4.4.2. Effect of Estrogen and Tamoxifen treatment 
Next, we wanted to test whether experimental modification of ER activity in T47D 
cells could create any change in senescence response. Again cells were plated at low-
density clonogenic conditions in complete DMEM, which contains weakly 
estrogenic phenol red (Berthois et al., 1986). Cells were cultured for seven days in 
order to obtain visible colonies. After seven days, culture medium was replaced with 
phenol-free DMEM complemented with charcoal-treated fetal calf serum, grown for 
two more days, then cultivated for four more days in the presence of E2 (10-9 M), 4-
hydroxytamoxifen (OHT; 10-9 M to 10-6 M), or an ethanol vehicle as control. Later 
experiment was stopped and SABG assay was performed (Figure 28B). Total and 
SABG positive cells were counted from 20 randomly selected colonies in 4 different 
areas for each treatment. As seen on the figure, complementation of the medium with 
10-9 M E2 caused inhibition of senescence almost 50%. Control cells generate 
colonies which display 31±13% SABG positivity on the other hand 10-9 M E2 
treated cells displayed 17±18% SABG positivity in their colonies (Figure 28C). 
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When we compared control and E2 treatment inhibition in senescence was 
statistically significant (p = 0.0093). 
 
In contrast to E2, OHT treatment of T47D cells creates a dose-dependent increase in 
the senescence response. At the maximum dose, 10-6 M OHT, we observed 90±13% 
SABG positivity in the colonies (Figure 28D), indicating that tamoxifen-mediated 
inactivation of ER can induce almost a complete senescence response in these cells 
(p < 0.0001). The increase in senescence rate was also significant with 10-7 M OHT 
(p = 0.0002). Our findings strongly suggested that the senescence observed in the 
SCP T47D cell line was due to a loss of expression and/or function of ER in a 
subpopulation of the progeny of these cells. 
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Figure 28: Estrogen treatment decreased generations of senescent progeny whereas 
Tamoxifen (4OHT) treatment increased  
A) Cells were seeded in low density condition and cultured seven days in 
standard culture medium. Then culture medium replaced with  replaced with phenol-
free DMEM complemented with charcoal-treated fetal calf serum, grown for two 
more days, then cultivated for four more days in the presence of E2 (10
-9
 M),  
B) 4-hydroxytamoxifen (OHT; 10-9 M to 10-6 M), or an ethanol vehicle as 
control. Later experiment was stopped and SABG assay was performed B) SABG 
positive and negative cells were counted from randomly selected colonies (n=20) and 
mean % SABG+ cells (± SD) were calculated  
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C) Inhibition by estrogen and activation by tamoxifen of senescence response was 
statistically significant (p < 0.0001) and (p = 0.0002) 
 
4.4.3. Effect of ER overexpression 
To confirm our results, we generated ER-overexpressing stable clones from T47D 
cell line. According to western blot result, three highest ER expressing clones were 
selected. Three other clones with endogenous expressions of ER were also selected 
from stable clones obtained with an empty vector (Figure 30A). BrdU assay was 
used for senescence response evaluation after low density cloning assay. Randomly 
selected colonies (n=10) from each clone were analyzed for total and BrdU+ number 
of cells (Figure 30B). Consistently higher levels of BrdU+ cells were observed with 
clones ectopically expressing the ER protein (Figure 30C). Overexpression of ER 
resulted in a significant increase in the BrdU+ progeny (p = 0.034). This finding is 
provided additional support to the previous data, which shows close relationship 
between ER expression and senescence in T47D cells. These results are indicating 
that acute lost of ER in T47D cells cause senescence phenotype.   Also lack of 
senescent progeny in ER (-) MDA-MB-231 cells shows that ER expression and 
senescence could be possible factors responsible from good prognostic features of 
Luminal A group of breast cancers.  
 
  
87 
 
Figure 29: ER overexpression caused increased BrdU incorporation in T47D clones.  
24 hour BrdU labeling and immunostaining in ER overexpressing clones (ER-5, ER-
7, and ER-26) and control ones (C-8, C-10, C-11)  
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Figure 30: ER overexpression inhibits generation of senescent progeny in T47D cells  
A) ER-overexpressing and control clones were established from T47D cells (C-8, C-
10, C-11 are control, ER-5, ER-7, ER-26 are overexpression clones). ER expression 
levels were checked by western blot. Calnexin was used as loading control B) For 
BrdU assay; colonies were generated, labeled with BrdU for 24 hours and 
immunostained. BrdU positive cells quantified by manually C) Graphic present mean 
% BrdU+ cells per colony. ER overexpressed clones showed significant increased in 
BrdU ratio (p=0.034). (Error bars represent mean ± SD) 
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4.4.4. Senescence in ER+ tumors 
All these data showed that there is a close relationship between ER expression and 
senescence in our ER+ cell line T47D. Also we wanted to analyze senescence 
phenotype in ER+ breast tissues to support our results with in vivo results. Breast 
tumor samples were collected from untreated patients. For obvious ethical reasons, it 
cannot be obtained fresh tumor tissues from tamoxifen treated patients. Therefore we 
analyzed small panel of 12 snapfrozen ER+ breast tumor tissues from 11 patients by 
SABG assay. The mean age of patients was 58±12 years, with a mixed menopause 
status (Table S2). Among these samples two tumors present SABG positive cells 
were scattered within the tumor area (%17)  
(Figure 31). These result showed that ER+ tumors produce senescent progeny at a 
lower rate. 
 
 
Figure 31: Detection of SABG+ senescent cells in estrogen receptor-positive breast 
tumors.  
6µ thick snap-frozen tumor sections were used to detect SABG+ cells. H&E: 
hematoxylin-eosin staining 
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Table 3: ER status, main pathological features of senescence staining (SABG) of 
breast tumors used in this study 
 
4.5. Senescence as a major determinant of breast cancer molecular heterogeneity 
  
4.5.1. Role of differentiation ability in SCP and ICP subtypes  
Estrogen receptor expression in breast tumors is very important determinant for anti-
estrogen therapies and for the prognosis. But even its importance we don’t have 
enough knowledge about distribution of ER+cells among the mammary epithelial 
cell hierarchy. Previous observations suggest that normal ER+ cells may represent 
either relatively differentiated luminal cells with limited progenitor capacity, or 
primitive progenitors with stem cell properties in the luminal cell compartment 
Luminal restricted progenitors (Stingl and Caldas, 2007). According to our finding 
we hypothesize that we hypothesized that ER+ SCP cells may differ from ER- ICP 
cells by their differentiation potential. 
To test this hypothesis we screened our 12 breast cancer cell lines by 
immunoperoxidase technique for their ability to generate stem/progenitor-like, 
luminal-like and myoepithelial-like cells. We used CD44 as a positive 
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stem/progenitor cell marker (Al-Hajj et al., 2003; Shipitsin et al., 2007), CD24, ER 
and CK19 as luminal lineage markers (Sleeman et al., 2006; Shipitsin et al., 2007; 
Yeh and Mies, 2008) and ASMA as a myoepithelial lineage marker (Yeh and Mies, 
2008) Representative pictures from marker studies are shown in Figure 33A-B and 
results are summarized in Figure 34. CD44 staining showed heterogeneous staining 
in all of the SCP cell lines. But 5 of the 7 cell lines from ICP subgroup only produced 
fully positive colonies.  This result displays that these cell lines cannot produce 
CD44- cells. One cell line (MDA-MB-453) was totally negative for CD44. SK-BR-3 
was showed heterogenic CD44 staining parallel to SCP group staining. When we 
compare the both subgroup’s results in terms of ability of generate both CD44+ and 
CD44- progeny it is mostly associated with the SCP phenotype (p =0.0046). 
 
In ER immunostaining, all of SCP cell lines showed heterogeneous and mostly 
positive staining whereas all seven ICP cell lines never produced ER+ cells. ER 
expression was also significantly associated with the SCP subtype (p = 0.0012). 
Moreover, we also found that ability to produce ASMA+ progeny was also 
significantly associated with the SCP subtype (p =0.0046). ICP cell lines did not 
generate ASMA positive cells. Also we noticed that under low-density clonogenic 
conditions two SCP cell lines generate rare ASMA+ cells compare to under high-
density conditions (Figure 32). This could be either ASMA+ cells are enhanced at 
high cell density, or these myoepithelial-like cells have limited survival ability under 
long-term culture conditions. 
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Figure 32: High density seeded MCF7 and T47D cells show more ASMA+ 
expression.  
 
We did not find a strong association between the expression of CD24 and CK19 
markers and cell subtype. All five SCP cell lines and three ICP cell lines generated 
heterogeneously staining colonies for CD24 expression. Similarly, all five SCP cell 
lines, as well as three ICP cell lines, expressed CK19, but homogenously. 
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Figure 33: Representative pictures from marker studies A) Senescent Cell Progenitor 
subtype cell lines B) Immortal Cell Progenitor subtype cell lines 
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Figure 34: Summary of marker study results in breast cancer cell lines 
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4.5.2. Correlation of SCP and ICP subtypes with different breast tumor molecular 
subtypes  
Gene expression profiling of breast cancer has been shown that breast cancer is not a 
single disease rather a group of molecularly distinct neoplastic disorder (Perou et al., 
2000; Sorlie et al., 2003; Sotiriou et al., 2003; Sotiriou and Pusztai, 2009). Also each 
molecular subgroup has different prognosis and therapeutic response (Sorlie et al., 
2003; Sotiriou and Pusztai, 2009).  
 
Therefore we wanted to analyze whether we could assign SCP and ICP cell lines to 
known molecular subtypes of breast tumors. For this study we conducted 
“hierarchical clustering” analysis which is a powerful technique for class discovery 
and prediction. The “intrinsic gene set” data generated by Sorlie et al. (2003) to 
classify breast tumors into five molecular subtypes was used to filter cell line data 
generated by Charafe-Jauffret et al. (2006). A set of 175 genes was common between 
the two data sets. Sixty-eight tumors and 31 cell lines were subjected to pair-wise 
complete-linkage hierarchical clustering and distance measurements.  With this 
analysis we observed two main clusters; one consisting of basal and luminal B 
subtype, and the other consisting of luminal A, ERBB2+ and normal like subtypes. 
When we investigate the breast cell lines in these clusters, we have interestingly 
observed that all SCP cell lines exist in the second branch containing; luminal 
subtype A, ERBB2+ and normal like subtypes, and these cell lines were mainly close 
to luminal subtype A. On the other hand, ICP subtype breast cell lines were in the 
first branch containing basal and luminal B subtypes, except MDA-MB-453. Four 
cell lines clustered with Luminal A tumor subclass, and one cell line with normal-
like subclass (Figure 35)  
In other words, we have found SCP subgroup of breast cancer cell lines in perfect 
concordance with the luminal A, ERBB2 plus and normal like subtypes, and the five 
of ICP breast cancer cell lines in perfect concordance with the luminal B and basal 
subtypes (p<0.01, Fisher’s exact test).Additionally, Luminal A tumors clustering 
with our SCP subtype cell lines display the longest tumor free, distant metastasis-free 
and overall survival rates. In contrast, basal and luminal B tumors clustering with our 
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ICP subtype cell lines have the worst prognosis, with shorter tumor-free, distant 
metastasis-free and overall survival times (Sorlie et al., 2003). 
 
Figure 35: Unsupervised hierarchical clustering of breast tumor and cell line gene 
expression data from Sorlie et al. (2003) and Charafe-Jauffret et al. (2006).  
Dendrogram displaying the relative organization of tumor and cell line data 
demonstrates that ICP cell lines cluster with basal and luminal A tumors in the same 
branch, except for MDA-MB-453. Senescent cell progenitor cell lines cluster with 
luminal A (BT-474, CAMA-1, MCF-7, T47D) and normal-like tumors (ZR-75-1). 
No data was available for MDA-MB-468. A dendrogram with sample IDs is 
provided in Figure 37. The “intrinsic gene set” data generated by Sorlie et al. (2003) 
was used to filter cell line data generated by Charafe-Jauffret et al. (2006). A set of 
175 genes was common between the two data sets. Sixty-eight tumors and 31 cell 
lines were subjected to pair-wise complete linkage hierarchical clustering and 
distance measurements. 
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4.5.3. Differential tumorigenicity of SCP and ICP subtypes  
With our cluster analysis result we observed that our SCP subgroup cell lines very 
well overlap with the luminal A type tumors which is a good prognostic group and 
ICP subgroup of cell lines overlap with the Luminal B and basal tumors which is bad 
prognostic group. Therefore we hypothesize that ability to generate differentiated and 
senescent progeny is indication of poor tumorigenicity and for ICP subgroup it is 
vice versa. To test this hypothesis we conducted nude mice tumorigenicity assay. 
Three SCP subgroup cell lines (MCF-7, T47D and CAMA-1) and three ICP 
subgroup cell lines (BT-20, HCC1937 and MDA-MB-453) were injected 
subcutaneously into CD1 “nude” mice. Tumor growth was monitored for 10 weeks at 
the injection sites. Nine animals implanted with SCP cell lines did not develop 
tumors and remained tumor-free for at least 10 weeks, whereas seven out of eight 
animals implanted with ICP cell lines developed subcutaneous tumors within five 
weeks of cell injection (Figure 36). We excluded one animal from the study, which 
died shortly after the cell injection of MDA-MB-453 ICP cell line. Data shows 
statistically significant difference between tumorigenicity of SCP subtype and ICP 
subtype cell lines (p = 0.0002). This result gives another invivo support to our 
hypothesis. 
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Figure 36: SCP subtype and ICP subtype shows differential tumorigenicity in nude 
mice.  
5x106 cells were injected to the subcutaneous. Three SCP subgroup cell lines (MCF-
7, T47D and CAMA-1) and three ICP subgroup cell lines (BT-20, HCC1937 and 
MDA-MB-453) were used in the study. Tumor growth was monitored for 10 weeks 
at the injection sites. Chart displays tumor-free survival following subcutaneous 
injection of cells. 
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Table 4: Gene clusters, genetic mutations and epigenetic changes of breast cancer 
cell lines  
 
 
 
A, amplified; BaA, basal A; BaB, Basal B; L, luminal; M, mutated; met, promoter methylated; unmet, 
promoter unmethylated; +/+, wild-type; -/-, homozygous deletion; unknown. 
1
 Neve et al. (2006); 
2
From Sanger, COSMIC data;  
3
Hollestelle et al. (2007); 
4
Paz et al. (2003); 
5
Runnebaum et al.(1991). 
Gene clusters, genetic mutations and epigenetic changes of breast cancer cell lines used in this study 
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Figure 37: Unsupervised hierarchical clustering of breast tumor and cell line gene 
expression data.  
This data is also described in Figure 35. Dendrogram shown here includes tumor and 
cell line sample IDs.  
 
4.6. Effect of Retinoic acid in breast cancer cell senescence 
 
Retinoids are physiological signaling molecules that play role in regulation of 
organismal development, tissue differentiation and cell death. Retinoids, natural or 
synthetic derivatives of vitamin A, act as regulators of transcription. Their effect on 
gene expression is mediated at the transcription level by binding to transcription 
factors formed through dimerization of retinoic acid receptors (RAR) and rexinoid 
receptors (RXR). These factors regulate transcription initiation by binding to retinoid 
response elements (RARE) in the promoters of target genes. 
 
It has been shown that Retinoids cause senescent like changes and growth arrest in 
MCF7 cells (Chang et al., 1999; Docmanovic et al, 2002) and human neuroblastoma 
cells (Wainwrigth et al., 2001). 
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We wanted to investigate the effect of Retinoids that causes differentiation associated 
with permanent growth arrest in our breast cancer cell lines. Therefore, we chose 
BT474, MCF7 (Napoli), Cama1 and BT-20 cell lines for low density cloning assay 
method. Cells were grown in the presence and absence of tRA until they generated 
colonies (10 days). As a tRA treatment dose, we applied 100nM tRA to the cells 
every 2 days, because this tRA dose was previously shown to successfully generate 
senescence in 6-9 days in MCF7 cells (Chang et al., 1999). After tRA treatment, 
cells were subjected to SABG staining and manually counted to analyze their 
senescence status.  The results obtained with SABG analysis showed that there was a 
measurable increase in SABG index and decrease in colony size of tRA treated 
MCF7 and Cama1 cells when compared with the untreated control group.  Especially 
in Cama1 cells, anti-proliferative effect was more profound than senescent effect 
(Figure 38) (Cells in tRA treated colonies were ranging 3-1cells/colony where cells 
in control group 110-43cells/colony). tRA treatment did not make any drastic change 
on SABG staining status or colony size of BT474. In BT20, tRA treatment only 
resulted with decreased in colony size (Figure 39). 
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Figure 38: SABG index and colony size after tRA treatment in MCF7 and Cama1 
cell lines for treated and untreated groups. 
RA application into MCF7 and Cama-1 cells resulted with decreased in colony size 
and increased in SABG index. Effect of RA was more profound in Cama-1 cells. By 
RA treatment colony sizes of Cama-1 cells were decreased from ~ 100 cells/colony 
to ~ 3 cells/colony and most of the cells in colonies were SABG positive. 
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Figure 39: SABG index and colony size after tRA treatment in BT474 and BT20 cell 
lines for treated and untreated groups. 
Not significant chances were observed either colony size or senescent index in BT-
474 and BT-20 cell lines between tRA treated and untreated group. 
 
Moreover, according to the results above, tRA dose was very high in Cama1 cells. It 
was totally blocked the proliferation of these cells. Then, we decided to use dose 
curve for tRA in Cama1 cells to find an optimal dose range to detect senescence 
effect more clearly.  By performing dose curve for tRA, the dose range for 
senescence effect could be obtained within 1.5 - 0.75 nM tRA, which was a very low 
dose.  As a result of these experiments, senescence induction and growth inhibition 
effect of tRA was observed not only in MCF7 cell line but also in Cama1 cell line. 
But the same effect was not observed in BT474, which is in the same molecular 
subgroup with MCF7 and Cama1. tRA didn’t cause senescence induction but caused 
growth inhibition in BT20 cells (Figure 40).  
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Figure 40: SABG index and colony size in Cama1 cells after different dose of tRA 
treatment. 
Optimum senescence effect was obtained in 1.5 - 0.75 nM tRA dose range. In these 
doses less growth inhibition were observed. By this way senescence phenotype more 
clearly evaluated in Cama-1 cells.   
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CHAPTER 5.  DISCUSSION AND FUTURE PERSPECTIVES 
 
Most of the primary cells undergo a limited number of cell division and then they 
stop to proliferate which is known as senescence. It has been suggested that 
senescence presents a barrier against tumorigenesis. To become immortalized, 
human mammary epithelial cells should pass two senescence barriers known as 
“selection” and “crisis” (Romanov et al., 2001). P21Cip1/p53 and p16INK4a/Rb 
pathways have been shown to play crucial role in the induction of senescence (Ben-
Porath and Weinberg, 2005). 
 
In contrast to general characteristic of cancer, limitless capacity of proliferation, we 
observed senescence in a group of breast cancer cell lines, later we named it SCP 
(senescent cell progenitor) group. our breast cancer cell line panel was screened by 
using SABG assay as a senescence marker in low density clonogenic conditions. 
Low density cloning assay allowed us to follow progenies generated by a few 
hundred cells under the same experimental conditions. Clonogenic assays are very 
good methods to detect stem/progenitor cells and properties of their progeny (Stingl 
J, 2009). Our screening showed that our breast cancer cell line panel can be divided 
into two subgroups according to their ability to produce senescence progeny. First 
group is called SCP (senescent cell progenitor) group which produces high level of 
SABG positive cells and second group is called ICP (immortal cell progenitor) group 
which cannot generate SABG positive cells. Moreover, long time BrDU labeling and 
co-staining with SABG experiment showed that there was low incorporation of 
BrDU in senescent cells. This shows us that these senescent cells are differentiated 
cells. 
 
Senescence that we observed in our breast cancer cell lines does not represent 
characteristics of replicative senescence. This is because, after generation of isogenic 
clones from SABG positive breast cancer cell lines, we couldn’t observe fully 
senescence in these clones even after they passed many population doublings (>60) 
in the cell culture. 
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P53 and p16
INK4a
/Rb are two main pathways for senescence. P53 mediates its effect 
by p21
Cip1
. Therefore we analyzed whetherp16 and p21 expressions are related with 
SCP group of cell lines. All of the breast cancer cell lines were screened by 
immunoperoxidase assay in low density clonogenic conditions. There was no 
correlation found with p16 expression in SCP group. But importantly, it was found 
that 4 out of 5 SCP cell line shows strong, heterogenic, nuclear p21
Cip1 
staining. Also, 
SABG and p21
Cip1
 co-staining and SABG and p16
INK4a
 co-staining were performed 
in T47D and MDA-MB-231 cell lines. P21
Cip1
 positive cells were mostly senescent 
cells in T47D. MDA-MB-231 showed no staining for SABG and p21
Cip1
. These 
results showed significant correlation between p21
Cip1 
increase and SCP group.  We 
confirmed these results by down regulating p21
Cip1 
in T47D cell line. We observed 
increase in BrdU incorporation in T47D-p21sh clone compared to control clone 
(from 48±20% to 65±12% per colony). All these data indicated that p21Cip1 is 
partially responsible from generation of progeny in SCP group.  
 
ER expression is one of the important markers in breast cancer to evaluate the 
prognosis of the disease. P21
Cip1
 is target of p53. E2 mediates p21
Cip1
 inhibition by c-
myc (Mukherjee and Conrad, 2005). Myc gene is direct target of ER complex (Dubik 
and Shiu, 1992). Therefore we hypothesize that ER receptor could play a role in the 
generation of senescent progeny in SCP group. First of all, our SCP group expresses 
ER, but ICP group of breast cancer cell lines don’t express it. We checked whether 
senescence phenotype correlates with ER expression in SCP group. Co-staining of 
ER and SABG displayed that ER-negative cells were mostly in senescent state. 
Moreover, in T47D cells, estrogen treatment inhibits generation of senescent progeny 
whereas tamoxifen treatment (in 10
-6
M concentration) increased it up to 90%. These 
results showed direct involvement of ER in senescence progeny generation in SCP 
group of breast cancer cell lines. We also confirmed our results by overexpressing 
ER in T47D cell lines. ER-overexpressing T47D clones increasingly incorporate 
BrdU compared to control clones. These data correlates well with the clinical data 
which shows good prognosis, good response to anti-estrogen treatment and relapse 
free survival for ER-positive Luminal-A group of breast cancer (Sorlie et al., 2003). 
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Gene expression profiling of breast cancers revealed several subtypes of breast 
cancer (Perou et al., 2000; Sorlie et al., 2003). To understand whether our SCP and 
ICP subgroup correlated with this classification, we performed “hierarchical 
clustering” analysis on Sorlie et al. (2003) breast tumor data and Charafe-Jauffret et 
al. (2006) cell line data. With this analysis we observed two main clusters; one 
consisting of basal and luminal B subtype, and the other consisting of luminal A, 
ERBB2+ and normal like subtypes. We have found that SCP subgroup of breast 
cancer cell lines are in perfect concordance with the luminal A, ERBB2 plus and 
normal like subtypes, and the five of ICP breast cancer cell lines are in perfect 
concordance with the luminal B and basal subtypes. This shows that our SCP group 
is phenotypically similar to Luminal A group of breast cancers. 
 
To test the tumorigenicity potential of our SCP and ICP group, we injected 3 cell 
lines from SCP group (MCF-7, T47D and CAMA-1) and 3 cell lines from ICP group 
(BT-20, HCC1937 and MDA-MB-453) subcutaneously into nude mice. SCP cell 
lines did not develop tumors and remained tumor-free for at least 10 weeks, whereas 
seven out of eight animals implanted with ICP cell lines developed subcutaneous 
tumors within five weeks of cell injection. This study results correlates with all the 
other data. Our SCP group cell lines are poorly tumorigenic and locate in Luminal A 
group breast cancer cluster and clinically this group has longest tumor-free, distant 
metastasis-free and overall survival rates. We also screened a small panel of breast 
tumor samples (12 snapfrozen ER+ breast tumor tissues from 11 patients) with 
SABG assay. These samples were from untreated patients. We detected positive 
SABG staining in only two tumor samples. It would be more informative to screen a 
bigger panel of breast tumor tissues.   
 
Breast cancer is a heterogeneous disease in terms of histopathological and clinical 
features (Stingl and Caldas, 2007). Mammary epithelium consist of two epithelial 
lineages, luminal and myoepithelial cells. Recent studies indicate that mammary 
epithelium is organized hierarchically different cell that ranges from stem cells to 
differentiated cells (Stingl J, 2009). To understand differentiation ability of our breast 
cancer subtypes, we tested different marker expression status. We used CD44 as a 
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stem/progenitor cell marker, CD24, ER and CK19 as luminal lineage markers and 
ASMA as a myoepithelial lineage marker. SCP group of cell lines were heterogenous 
for all of the marker expressions. Only ZR-75-1 showed negative ASMA staining. It 
means that they contain CD44
+
/CD24
- 
stem cells and also differentiated cells. These 
cell lines can express epithelial marker (CK19) and as well as myoepithelial marker 
(ASMA). This result provides evidence that they have an ability to generate 
differentiated cells. This data is also important because it shows heterogenic 
characteristics and stem/progenitor potential of Luminal-A group of cancers. ICP 
group of cells (5/7) generated only CD44
+
 and CD24
-
 cells. They couldn’t generate 
ASMA-positive cells. This can be interpreted as: “ICP group cell lines lost their 
differentiation ability and block in stem/progenitor cell stage”. Therefore they are 
highly tumorigenic clinically. Moreover, MDA-MB-453, SK-BR-3 and MDA-MB-
468 cell lines presented similar CK19 and CD24 staining pattern with SCP group in 
marker studies. But they are not SABG positive and don’t express ER and ASMA.  
In addition CD44 expression in these three cell lines were vary. These results suggest 
that MDA-MB-453, SK-BR-3 and MDA-MB-468 cell lines still may retain partial 
differentiation ability but possibly not as much as SCP group. It is possible to think 
that these group could be prospective target to induce senescence and differentiation 
in order to decrease their tumorigenecity potential. 
 
During my study we were also interested in other possible factors that could play role 
in senescence phenotype that we observed in our breast cancer cell lines. These are 
reactive oxygen species (ROS) and retinoids. 
 
Cellular senescence can be induced by different stimuli. One of them is oxidative 
stress. We hypothesized that senescence that we observed in breast cancer cell lines 
can be related with ROS accumulation in the cell. Therefore, firstly, ROS 
accumulation in Cama1 and MDA-MB-468 cells were analyzed by DCFH and 
MitoTracker co-staining. Not at day 10 but at day 13, ROS accumulation in Cama1 
cells were very strong and NAC treatment showed significant decrease in ROS level 
compared to no observable change in MDA-MB-468 cells. Also, MitoTracker 
staining which provides information about mitochondrial ROS didn’t show any 
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difference neither in Cama1 nor in MDA-MB-468 cell line. This result suggests that 
there is a gradual intracellular ROS accumulation occuring in Cama1 cells and it is 
originated from intracellular source other than mitochondria.  NBT (nitroblue 
tetrazolium) and SABG co-staining in BT-474 result provide evidence that 
senescence positive cells have ROS accumulation. To confirm our results we decided 
to check whether we can inhibit senescence by NAC which is a scavenger of ROS. 
Cama1 cells seeded at low density and treated with 10 mM NAC. Experiments were 
stopped at day 10 and 15 and next, SABG was performed. SABG results showed that 
there is a significant decrease in senescence with NAC treatment at day 15. Sources 
of cellular ROS include leakage from the mitochondrial electron transport chain, 
ROS-generating plasma membrane and cytosolic enzymes. NADPH oxidases (NOX) 
are membrane located electron-transporting enzymes. Their primary function is 
generation of reactive oxygen species (ROS). There is significant supporting 
evidence that the role of ROS which is produced by NADPH oxidases, is the 
regulation of intracellular signaling cascades in different types of cells (Droge W, 
2002). Therefore we wanted to analyze the expression pattern of Nox genes (Nox1, 
Nox2, Nox3, Nox4 and Nox5) in our breast cancer cell line panel with RT-PCR. We 
found increased expression of Nox2 and Nox5 in two of the SCP subgroup of cell 
lines, but not in all of them. Real time PCR results also confirmed RT-PCR data.  
These results suggested that there is a correlation between ROS accumulation and 
senescence induction in SCP subgroup of cell lines. Increased level of ROS that we 
observed in Cama1 and BT-474 cells probably are not originated from mitochondria. 
Nox2 and Nox5 could be potential candidates. But increased expression in Nox2 and 
Nox5 were not observed in all SCP group. Therefore other cellular ROS providers 
might be considered for future experiments. According to our data, it may be 
possible to state that increased level of ROS triggers some redox-sensitive pathways, 
causing changes in gene expression and consequently senescence response. In 
addition, it has been shown that p21
Cip1
 increased cellular ROS level both in normal 
fibroblasts and in p53-negative cancer cells and p21-induced senescence was rescued 
by using NAC (Macip et al., 2002). This interesting finding correlates with our data 
even though their experiments were done in another type of cancer cell line.   
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Retinoids are physiological signaling molecules that play role in the regulation of 
organismal development, tissue differentiation and cell death. Retinoids have been 
used in the treatment of promyelocytic leukemia (APL) and premalignant diseases 
such as acute leukoplakia, actinic keratosis, cervical dysplasia and xeroderma 
pigmentosum (Altucci and Gronemeyer, 2001). It has been shown that retinoids 
cause senescent like changes and growth arrest in MCF7 cells (Chang et al., 1999; 
Docmanovic et al, 2002) and human neuroblastoma cells (Wainwrigth et al., 2001). 
Also Chang et al. detected senescence induction by retinoic acid treatment in vivo. 
They used H-Ras transformed MCF10ANeoT human breast epithelial cell line and 
transplanted in mammary gland of nude mice. 4-HPR (4-hydroxyphenyl retinamide) 
- threated mice developed less malignant tumors compared to untreated mice. 
Moreover, they observed high SABG staining in drug-treated tumor compare to 
untreated tumor (Chang et al., 1999). Since we consider our senescence phenotype as 
terminal differentiation stage in our SCP group cell lines, we hypothesized that 
retinoids could play a role in this phenomenon. 100nM tRA was applied into MCF7, 
Cama1, BT-474 and BT-20 cell lines in low density clonogenic conditions. 
Experiment was stopped at day 10 and subjected to SABG assay. RA treatment 
resulted in growth inhibition and senescence in MCF7 and Cama1 cell lines, showing 
no difference in BT-474 and some degree of growth inhibition in BT-20 cell line.  
But growth inhibition was very severe in Cama1 cell line. This result was very 
dramatic in Cama1 cell line. Some of the Cama1 colonies were 100% SABG- 
positive. But these colonies were very small. So we decided to use tRA dose curve in 
order to find optimum dose in which minimal growth inhibition and maximum 
senescence effect are observed. 1.5-0.75 nM range of tRA treatment in Cama1 cells 
resulted in high SABG index and less growth inhibition. This observation suggests 
that growth inhibitory effect of tRA is very prominent in Cama1 cells.  But we still 
observed increased senescence response in 2 out of 3 SCP subgroup of cell lines. 
Probably it would be necessary to test other SCP group and ICP group cell lines with 
tRA treatment and compare tRA effect.   
 
We think our results are important due to a couple of aspects. We provide evidence 
that Luminal A type of breast tumors has differentiation ability and senescence, 
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which is a terminal differentiation stage of cells, could be a reason of their good 
prognostic features. Senescence induction can be used in these cancers as a 
therapeutic approach. In this study, we also provide a group of cell lines as a model 
for future studies to explore senescence and differentiation mechanisms in more 
details.  
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Novelty and impact: Breast cancer heterogeneity is believed to be a sign of tumor initiation from 
different progenitor lineages involved in mammary epitheliogenesis. Here, we show that breast 
cancer cell lines clustering with luminal A/normal-like and basal/luminal B tumors respectively, 
differ from each other by the ability to generate differentiated and senescence-arrested progeny. 
Less tumorigenic senescent cell progenitor cell lines generate both luminal- and myoepithelial-like 
cells. In contrast, more tumorigenic immortal cell progenitor cell lines are defective in their ability 
to generate differentiated progeny.  Our findings may have prognostic relevance and serve as a 
basis for therapeutic induction of differentiation and senescence in breast cancer.        
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Abstract 
Breast cancer displays distinct subtypes, such as luminal A, luminal B, and basal-like. The 
prognosis and therapeutic response of each subtype is different. The mechanisms involved in 
the generation of these tumor types are poorly understood. Our aim was to test whether the 
ability to generate senescent progeny contributes to breast cancer heterogeneity. A panel of 12 
breast cancer cell lines, 31 isogenic clones, and 12 breast tumors were used. We classified 
breast cancer cell lines into senescent cell progenitor (SCP) and immortal cell progenitor 
(ICP) subtypes. All ER+ cell lines tested, and some ER-positive (ER+) breast tumors 
displayed senescence. Acute loss and tamoxifen-mediated inactivation of ER triggered a 
robust senescence response in SCP type T47D cell line.  In contrast, estrogen treatment and 
p21Cip1 knockdown inhibited senescence. Breast cancer cell subtypes displayed divergent 
ability to produce differentiated progeny. The SCP subtype cells produced CD24+ or ER+ 
luminal-like and ASMA+ myoepithelial-like progeny, in addition to CD44+ stem/progenitor-
like cells. In contrast, ICP cell lines acted as differentiation-defective stem/progenitor cells. 
Some cell lines generated only CD44+/CD24-/ ER-/ASMA- progenitor/stem-like cells, and 
others only CD24+/ER- luminal-like, but not ASMA+ myoepithelial-like cells. SCP cell lines 
were less tumorigenic, and they clustered with luminal A/normal like tumors. In contrast, ICP 
subtypes were more tumorigenic, and they clustered together with basal/luminal B tumors. 
Our results show that breast cancer cell lines clustering with luminal A/normal-like and 
basal/luminal B tumors respectively, differ from each other by the ability to generate 
differentiated and senescence-arrested progeny.  
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 Human breast cancers are heterogeneous, both in their pathology and in their molecular 
profiles. First, the patterns of genetic changes such as chromosomal aberrations and gene mutations 
observed in breast tumors indicate that breast tumorigenesis does not follow a stepwise linear 
progression from well-differentiated to poorly differentiated tumors.1 Second, gene expression 
analyses classify breast tumors into distinct subtypes, such as luminal A, luminal B, ERBB2-
positive (ERBB2+) and basal-like.2-4 The prognosis and therapeutic response of each subtype is 
different. Luminal A cancers are mostly estrogen receptor--positive (ER+) and sensitive to 
antiestrogen therapy, with best metastasis-free and overall survival rates. Luminal B tumors have 
incomplete antiestrogen response and lower survival rates. Basal-like and ERBB2+ tumors are ER- 
and display the worst survival rates.3,4 
 The mechanisms involved in the generation of different breast tumor types are poorly 
understood. According to one hypothesis, they may derive from different progenitor lineages 
involved in mammary epithelial cell differentiation.1 The mammary gland is composed of 
differentiated luminal and myoepithelial cells that are generated from multilineage, luminal-
restricted and myoepithelial-restricted progenitors originating from a hypothetical breast epithelial 
stem cell. Different types of breast cancers are proposed to originate from such stem or progenitor 
cells at different stages of commitment and differentiation, as observed in hematological 
malignancies.1,5 In line with this hypothesis, CD44-positive/CD24-negative (CD44+/CD24-) 
mammary-tumor-initiating cells, also called “breast cancer stem cells” have been isolated from 
primary breast tumors,6-8 and breast cancer cell lines.7-12 Breast cancer stem cells have also been 
generated from human mammary epithelial cells through epithelial-mesenchymal transition.13,14 
CD44+ cells are more tumorigenic than CD44- cells. CD44+ mammary tumor-initiating cells 
represent a fraction of breast tumors, and they give rise to tumors composed of both CD44+ and 
CD44- cells, as observed in the original tumors.6  
 Breast cancer cell lines often reproduce the status of primary tumors. They harbor tumor-
initiating cells at different rates and such tumor-initiating cells generate tumors composed of 
heterogeneous cell populations.11,12 CD44+/CD24- cells have also been identified in normal 
mammary epithelium, in strong support of stem/progenitor cell origins for breast cancer.15 Tumor-
initiating cells have been identified from both luminal and basal-like cell lines.9,11,12 Similarly, 
CD44+/CD24- stem-like cells were detected in both basal and non-basal breast tumors, with higher 
frequencies in basal tumors.16 However, unlike hematological malignancies, specific stem- or 
progenitor cell-type origins have not been assigned to different breast tumor subtypes. It is also 
unknown if the differential prognosis and the therapeutic responses of distinct tumor subtypes can 
be related to tumor-progenitor cell types. If we assume that stem cells and downstream progenitor 
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cells at different stages of commitment have sensitively different progenitor potential, this should 
have a direct effect on tumor prognosis and therapeutic response. The lack of a comprehensive map 
of mammalian epitheliogenesis and the extreme heterogeneity of breast tumors appear to be the 
major obstacles in resolving these critical issues. 
Here, we describe the use of cellular senescence as a mark of terminal differentiation to 
characterize the progenitor potential of breast cancer cells. Normal mammary epithelial cells 
undergo two successive senescence states, termed “stasis” and “agonescence,” from which 
spontaneous immortalization has not been observed.17,18 However, replicative immortality can be 
induced in these cells by ectopic expression of telomerase reverse transcriptase (TERT) and 
inactivation of senescence checkpoints.19,20 Similarly, breast cancer cells can acquire 
immortalization by genetic/epigenetic inactivation of senescence checkpoints and reactivation of 
TERT expression.18 The abundance of non-tumorigenic and differentiated cells both in breast 
tumors and cell lines strongly suggests that replicative immortality cannot be assigned to all cells 
within a tumor or a cancer cell line, and that spontaneous senescence after a limited number of 
population doublings (PD) is likely to occur. If this hypothesis is correct, then the rate of generation 
of senescent progeny may reflect the potential of a cancer stem/progenitor cell to produce 
terminally differentiated progeny. We tested this hypothesis using a panel of luminal and basal-like 
breast cancer cell lines (Table 1). Although a single cell line is not representative of breast tumor 
heterogeneity, a panel of cell lines might reproduce the heterogeneity that is observed in primary 
breast tumors, albeit with some limitations.5,21 Therefore, we hoped that in vitro studies with a panel 
of cell lines might help to better understand breast tumor heterogeneity.  
 Our senescence tests allowed us to classify breast cancer cell lines as senescent cell progenitor 
(SCP) and immortal cell progenitor (ICP) subtypes. We also show that senescent progeny are 
observed exclusively in estrogen receptor- (ER)-positive cells, as a result of ER inactivation, 
partly mediated with p21Cip1 protein. The ability to produce senescent progeny was associated with 
the ability to produce luminal-like and myoepithelial-like progeny from stem/progenitor-like cells. 
In contrast, most of the cell lines lacking senescent progeny were also unable to generate 
differentiated progeny. Finally, we show that SCP subtype cell lines cluster with luminal A/normal-
like breast tumor types and are less tumorigenic, whereas ICP subtype cell lines cluster with 
luminal B/basal-like tumor types and are more tumorigenic. 
 
Material and Methodes 
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Clinical samples and cell lines 
 Freshly frozen tumor specimens were collected at Ankara Numune Hospital. The use of the 
tissue material was approved by the Research Ethics Committee of Ankara Numune Research and 
Teaching Hospital. Consents were obtained in accordance with the Helsinki Declaration. Breast 
cancer cell lines used in this study were listed in Table 1. The authenticity of cell lines was verified 
by short tandem repeat profiling, as recommended by ATCC (http://www.lgcstandards-atcc.org). 
Isogenic clones from T47D (n=20) and BT-474 (n=11) cell lines were obtained from single cell-
derived colonies. Briefly, cells were plated in 96-well plates to obtain single colonies in less than 
70% of wells. Isolated colonies were then tranferred to progressively larger wells, and to T25 
flasks. Clones were subcultivated weekly at 1:4 dilution ratios, and maintained in culture for 25-30 
passages to reach to >60 PD before testing.   
 
Primary antibodies 
 The following antibodies were used: anti-CD44 (559046; BD Pharmingen), anti-CD24 
(sc53660; Santa Cruz,), anti-ASMA (ab7817; Abcam), anti-CK19 (sc6278; Santa Cruz,), anti-
p21Cip1 (OP64; Calbiochem), anti-p16Ink4a (NA29, Calbiochem), anti-ER (sc8002; Santa Cruz). 
 
Low-density clonogenic assays 
 Cells were seeded as low-density on coverslips in six-well plates (500-2000 cells, according 
to plating efficiency) allowed to grow in DMEM supplemented with 10% fetal calf serum, with 
medium change every three days, until they formed colonies of a few hundred cells. Depending on 
cell lines, this took one to two weeks. For BrdU assays, cells were labeled for 24h prior to 
immunocytochemistry.  
 
Immunocytochemistry  
 For simple immunoperoxidase assays, cells were fixed with cold methanol for five minutes, 
then blocked with 10% FCS in PBS for 1h. This was followed by incubation with primary antibody 
for 1h. Cells were then washed with PBS three times and subjected to immunostaining using the 
Dako-Envision-dual-link system and the Liquid DAP Substrate chromogen system (Dako, CA, 
USA), according to the manufacturer’s instructions. Hematoxylin was used as a counter-stain when 
the visualization of cells was necessary. For SABG-immunoperoxidase co-staining studies, unfixed 
cells were first subjected to SABG assay, and then fixed prior to immunostaining assays. 
Page 5 of 31
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Hematoxylin counter-staining was omitted for co-staining experiments, unless cells were negative 
for SABG staining.  
 
Immunoblot analyses 
 Cell pellets were incubated in NP-40 lysis buffer [50 mM Tris–HCl, pH 8.0, 250 mM NaCl, 
0.1% Nonidet P-40 and 1Xprotease inhibitor cocktail (Roche)] for 30 minutes in a cold room. Then 
cell lysates were cleared by centrifugation. Bradford assay was performed to quantify the protein 
concentration of the cell lysates. 30 µg of protein was denatured and resolved by SDS-PAGE using 
10% or 12% gels. Then, proteins were transferred to the PVDF or nitrocellulose membranes. 
Membranes were treated for 1h with blocking solution tris-buffered saline containing 0.1% Tween-
20 and 5% non-fat milk powder (TBS-T) and probed with primary antibody for 1h. Next, 
membranes were washed three times with TBS-T and incubated with HRP-conjugated secondary 
antibody for 1h. Then, immunocomplexes were detected by ECL-plus (Amersham) kit on the 
membrane. The -tubulin was used as an internal control.  
 
Senescence-associated beta-galactosidase (SABG) assay and BrdU/SABG co-staining 
 SABG activity was detected as described,22 except that cells were counterstained with 
eosine or nuclear fast red, following SABG staining. For BrdU/SABG co-staining, cells were 
labeled with BrdU (10 g/ml) for 24h in freshly added culture medium, and tested as described.23 
For co-staining, cells were first subjected to SABG assay, then fixed in 70% methanol and 
subjected to BrdU immunostaining.  
 
Estrogen and tamoxifen treatment 
 Cells were seeded under low-density clonogenic conditions onto coverslips in six-well 
plates, and cultivated in standard culture medium for seven to eight days. Then, cells were fed with 
phenol red-free DMEM (Gibco) supplemented with 5% charcoal-stripped fetal calf serum for 48h, 
followed by two successive 48h treatments with 10-9 M E2 (17-estradiol; Sigma), 10-6-10-9 M 
4OHT (4-hydroxytamoxifen; Sigma) or an ethanol vehicle, under the same conditions. Colonies 
were then subjected to SABG assay. Each experimental condition was conducted in triplicate and 
experiments were repeated three times.  
 
Generation of estrogen receptor-overexpressing clones 
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 T47D-iso23 cells were transfected with the expression vector pCMV- ER (ref. 24) or an 
empty vector using FuGENE-6 (Roche). ER overexpressing and control clones were selected with 
500g/ml G418 for three weeks. Isolated single-cell-derived colonies were picked and expanded in 
the presence of G418.  
 
Lentiviral infection and generation of p21Cip1 knock-down clones  
 We used mission shRNA plasmid pLKO.1<-puro-p21 (NM_000389.2-640s1c1, Sigma) for 
p21cip1 knockdown experiments. Control vector shRNA-pGIPz-SCR-puro and helper packaging mix 
(Invitrogen) were also used. HEK293T co-transfected with the appropriate vector and packaging 
mix, using CalPhos Mammalian Transfection Kit (Clontech), following the manufacturer's 
instructions. After 48h of culture, virus-containing culture media were collected, filtered and used 
to infect T47D-iso23 cells. After four hours of infection, stable cells were selected with 1 g/ml 
puromycin for seven days.  
 
Nude mice tumorigenicity assays 
 MCF-7, T47D, CAMA-1, BT-20, HCC1937 and MDA-MB-453 cells (5x106) were injected 
subcutaneously into CD-1 “nude” mice (Charles River). In order to minimise hormonal effects on 
tumor growth, male animals were used with no estrogen complementation. Local tumor growth was 
monitored for 10 weeks. All animal experiments were pre-approved by Bilkent University Animal 
Ethics Committee. 
 
Cluster analysis 
 The two-channel microarray data containing 8102 cDNA genes/clones, generated by Sorlie 
et al.2 were downloaded from the Stanford Microarray Database (SMD) (http://genome-
www.stanford.edu/MicroArray/).  In the downloading process, “log (base 2) of R/G Normalized 
Ratio (median)” parameter was used for data filtering.  We have median-centered expression values 
for each array. We selected arrays and genes with greater than 75% good data (representing the 
amount of data passing the spot criteria). Sixty-eight tissue samples were obtained according to this 
criterion and annotated with the subtypes described by the authors, found in “Supplementary 
Information” of the data set in SMD. The expression values of “500 gene signature,” defined by the 
authors, were extracted from the data. Gene expression profiles of 31 breast cancer cell lines 
performed by Charafe-Jauffret et al.,25 using the whole-genome cDNA microarray Affymetrix 
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HGU-133 plus 2, was obtained from the “Supplementary Table” of the article. The authors filtered 
genes with low and poorly measured expression, and with low expression variation, retaining 15, 
293 genes. After log transformation of the data, we median normalized the arrays of the data in R 
language, using the Bioconductor biostatistical package (www.r-project.org/ and 
www.bioconductor.org/). The “500 gene signature” tumor data2 and the normalized breast-cancer 
cell line data25 were combined with respect to probe IDs using a set of customized perl routines 
(source codes are available upon request). A set of 175 genes was common. “Median center” 
normalization of genes was made for the merged data set for the total samples. We performed 
unsupervised hierarchical clustering with the 99 samples, including 31 breast cell line25 and 68 
breast tumor 2 samples by pair-wise complete-linkage hierarchical clustering parameter, using the 
Gene-Pattern program. The Pearson correlation method was used for distance measurements. 
Clustering was visualized by java treeview, again using Gene-Pattern 
(http://www.broad.mit.edu/cancer/software/genepattern/).  
 
Statistical analyses 
 Significant differences were evaluated using unpaired Student's t test for compared samples 
sizes of 10 or higher. Otherwise, one-tailed Fisher's exact test was used with 2 × 2 tables; p < 0.05 
was considered statistically significant. On the graphical representation of the data, y axis error bars 
indicate the standard deviation for each point on the graph.  
 
Results 
 
Classification of breast cancer cell lines as senescent cell progenitor and immortal cell progenitor 
subtypes  
 Clonogenic assays have been successfully used to test the abilities of self-renewal and 
generation of phenotypically distinct progeny of mammary stem/progenitor cells.26 We previously 
applied this technique to test the ability of cancer cells to produce progeny with replication-
dependent senescence arrest.23 Cells are plated under low-density clonogenic conditions and 
cultivated for one to two weeks until individual cells perform eight to ten PD and generate isolated 
colonies composed of several hundred cells. This method permits the tracing of progenies generated 
by a few hundred cells under the same experimental conditions.  Here, we used low-density 
clonogenic assay to analyze a panel of 12 breast cancer cell lines, composed of luminal (n=7) and 
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basal (n=5) subtypes (Table 1). Our study classified the tested cell lines into two major subtypes. A 
group of cell lines generated colonies with high rates of senescence, while others did not produce 
appreciable amounts of senescent cells. Representative pictures of colonies subjected to SABG 
assay are shown in Fig. 1a.  The percent of SABG+ progeny was calculated by manual counting of 
at least 10 different colonies for each cell line. Colonies derived from five cell lines generated 
SABG+ cells at high rates (means: 12-40%) Senescence rates were negligible (means: 0-5%) in the 
progeny of the remaining seven cell lines. The first group that we named here as “senescent cell 
progenitor” (SCP) subtype included T47D, BT-474, ZR-75-1, MCF-7 and CAMA-1 cell lines. The 
second group named “immortal cell progenitor” (ICP) subtype, included MDA-MB-453, BT-20, 
SK-BR-3, MDA-MB-468, HCC1937, MDA-MB-231 and MDA-MB-157 (Fig. 1b).  
 In order to verify whether the occurrence of senescent cells in the SCP group was intrinsic to 
each cell line or due to the presence of a side population, we generated clones from T47D (n=20) 
and BT-474 (n=11) cell lines, and subjected them to SABG assay at different intervals. All clones 
acted similarly to their respective parental cell lines with similar rates of SABG+ progeny. No clone 
gained the ICP phenotype. More importantly, none of the clones tested over a long period of time 
(>60 PD) entered full senescence (data not shown), unlike normal mammary epithelial cells that 
undergo two stages of senescence arrest over a period of 20 PD (Ref. 18). We also confirmed the 
senescence phenotype by a supplementary test based on 24h BrdU labeling assay under mitogenic 
conditions.27 In order to confirm the specificity of the BrdU assay, we performed co-staining for 
SABG and BrdU, as shown in Fig. 1c. Most of the time, individual cells of the colonies from 
CAMA-1, T47D, and clones T47D-iso23 and BT-474-iso23 displayed either SABG+/BrdU- or 
SABG-/BrdU+ staining.  This indicated that SABG+ senescent cells were at the terminal 
differentiation stage with irreversible loss of DNA synthesis ability. Our observations also indicated 
that SABG and BrdU tests could be used alternatively to identify senescent (SABG+/BrdU-) and 
immortal (SABG-/BrdU+) cells under our experimental conditions. 
 
Senescent cell progenitor phenotype is associated with p21Cip1 expression 
 Both p16Ink4a and p53 have been shown to be mediators of senescence arrest in mammary 
epithelial cells.17,19,20,28 The p21Cip1 is the major effector of p53 for cell cycle arrest and 
senescence.18 Therefore, we analyzed the expression of p16Ink4a and p21Cip1 in the cell line panel. 
Heterogeneously and strongly positive nuclear p21Cip1 immunoreactivity was observed in four of 
the five SCP cell lines, but not in any of the seven ICP cell lines (Fig. 2a). The association of 
p21Cip1 expression with the SCP subtype was statistically significant (p = 0.0100). We also 
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compared the expression of p16Ink4a. Two SCP cell lines displayed heterogeneously positive 
immunostaining, whereas three of seven ICP cell lines displayed homogenously positive staining 
(Supplementary Fig. S1). The difference of p16Ink4a expression between the two groups was not 
significant (p = 0.6893). These observations indicated that the SCP phenotype was associated with 
p21Cip1 but not p16Ink4a expression in breast cancer cell lines.  
To test whether p21Cip1 was directly involved in the senescence observed in SCP cells, we 
first performed p21Cip1/SABG staining in T47D-iso23 cells (hereafter termed T47D). A SABG+ 
signal was observed mostly in p21Cip1-expressing cells (). Next, we 
generated two derivative cell lines following infection of T47D with lentiviral vectors encoding 
p21Cip1 shRNA (T47D-p21sh) or a scrambled control (T47D-scr). Following the demonstration of 
p21Cip1 knockdown in T47D-p21sh cells by western blot assay (Fig. 2b), both cell lines were plated 
under low-density plating conditions, colonies were grown for 10 days, and subjected to SABG and 
BrdU stainings. It was not possible to quantify SABG+ cells in T47D-p21sh cells because they 
formed tight clusters in culture (data not shown). Therefore, we used BrdU staining as an alternative 
method for senescent cell quantification (Fig. 2c). Randomly selected colonies were counted for the 
number of BrdU+ and BrdU- cells (Fig. 2d). The T47D-scr cell line generated BrdU+ progeny at a 
rate of 48±20% per colony (n=18). Under the same conditions, T47D-p21sh cells displayed BrdU+ 
progeny at a rate of 65±12% per colony (n=18), with a significant (p = 0.0043) increase in the 
number of cells escaping terminal arrest (Fig. 2e). These results indicated that p21Cip1 was partly 
responsible for the induction of senescence observed in the progeny of T47D cells.  
 
The generation of senescent cell progeny is controlled by estrogen receptor  
 As stated above, p21Cip1 is a downstream target of p53 for senescence, but T47D cells do not 
express wild-type p53 (Table 1). Estrogen inhibits p21Cip1 expression29 by c-Myc-mediated 
repression,30 MYC gene being a direct target of ER complex.31 Therefore, we tested whether ER 
could be involved in the senescence observed in T47D cells. Data shown in Fig. 3a indicated T47D 
cells displayed nuclear ER immunoreactivity in their great majority, but some progeny was ER-. 
More interestingly, these ER- cells tended to be SABG+, suggesting that the senescence occurred in 
T47D cells as a result of ER loss. MD-MBA-231 cells, on the other hand, did not express ER at all, 
and they were SABG-, as expected. Thus, the senescence susceptibility was restricted to ER+ T47D 
cells, however the senescent cells no longer expressed nuclear ER protein.    
Next, we tested whether experimental modification of ER activity in T47D cells had any 
effect on senescence response. After plating at low-density clonogenic conditions, cells were grown 
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in regular cell culture medium that contained weakly estrogenic phenol red32 for seven days in order 
to obtain visible colonies. Then, the culture medium was changed with phenol-free DMEM 
complemented with charcoal-treated fetal calf serum, grown for two more days, then cultivated for 
four more days in the presence of E2 (10-9 M), OHT (10-9 M to 10-6 M), or an ethanol vehicle as 
control. Colonies were subjected to SABG staining (Fig. 3b). Total and SABG+ cells were counted 
from 20 randomly selected colonies for each treatment (Fig. 3c). Colonies grown in a phenol-free 
charcoal-treated control medium complemented with an ethanol vehicle only displayed 31±13% 
SABG+ cells. Complementation of this medium with 10-9 M E2 generated colonies with 17±18% 
SABG+ cells. The inhibition of senescence by E2 was nearly 50% and statistically significant when 
compared to ethanol-complemented control cells (p = 0.0093). In contrast to E2, OHT provoked a 
dose-dependent increase in the proportion of SABG+ cells. At the maximum dose used (10-6 M 
OHT), 90±13% of colony-forming cells displayed SABG+ signal (Fig. 3d), indicating that 
tamoxifen-mediated inactivation of ER can induce almost a complete senescence response in these 
cells (p < 0.0001). The increase in senescence rate was also significant with 10-7 M OHT (p = 
0.0002).  
Our findings strongly suggested that the senescence observed in the SCP T47D cell line was 
due to a loss of expression and/or function of ER in a subpopulation of the progeny of these cells. 
For confirmatory reasons, we constructed ER-overexpressing stable clones from T47D cells. Three 
clones with the highest ER expression were selected. Three other clones with endogenous 
expressions of ER were also selected from stable clones obtained with an empty vector (Fig. 4a).  
Progeny obtained from these six clones was tested by BrdU assay (3). 
Randomly selected colonies (n=10) from each clone were evaluated for total and BrdU+ number of 
cells (Fig. 4b). Consistently higher levels of BrdU+ cells were observed with clones ectopically 
expressing the ER protein (Fig. 4c). Overexpression of ER resulted in a significant increase in the 
BrdU+ progeny (p = 0.034). The protective effect of ER overexpression was not as important as the 
senescence-promoting effects of ER inhibition, probably because endogenous levels of ER are 
already quite high in T47D cells and the phenol red in the standard culture medium is weakly 
estrogenic.32 Nonetheless, these findings provide additional evidence of a close relationship 
between ER expression and senescence in T47D cells.  
The detection of senescent cells in the progeny of the T47D cell line was correlated with a 
heterogeneous loss of nuclear ER expression. The lack of senescent progeny in the ER- MDA-MB-
231 cell line indicates that senescence response is due to acute loss of ER in T47D cells, as, by 
definition, the growth of MDA-MB-231 cells is independent of ER expression.  
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The close relationship between ER and senescence in the ER+ T47D cell line, and the 
highly effective treatment of ER+ breast tumors with tamoxifen, which induced senescence in our 
experimental model, suggested that senescence induction might be a relevant mechanism involved 
in antiestrogen treatments. As fresh tumor tissues cannot be obtained from tamoxifen-treated 
patients for obvious ethical reasons, we analyzed untreated ER+ breast tumor samples for evidence 
of in vivo senescence. We screened a small panel of 12 snap-frozen ER+ breast tumor tissues from 
11 patients for senescence by SABG assay. The mean age of patients was 5812 yrs, with a mixed 
menopause status (Supplementary Table S1). Two tumors (17%) displayed SABG+ cells that were 
scattered within the tumor area (). Thus, ER+ breast tumors also produced 
senescent progeny in vivo, but at a lower rate.  
 
Senescent cell progenitor and immortal cell progenitor subtypes greatly differ in their ability to 
differentiate into luminal and myoepithelial cell types 
 The cellular specificity of ER among the mammary epithelial cell hierarchy is poorly 
understood. Previous data suggest that normal ER+ cells may represent either relatively 
differentiated luminal cells with limited progenitor capacity, or primitive progenitors with stem cell 
properties in the luminal cell compartment.1,33,34 Based on the close association between senescence 
(that can be considered a manifestation of terminal differentiation) and loss of ER positivity, we 
hypothesized that ER+ SCP cells may differ from ER- ICP cells by their differentiation potential.  
We surveyed a few hundred single-cell-derived colonies from each of the 12 cell lines for 
production of stem/progenitor-like, luminal-like and myoepithelial-like cells. We used CD44 as a 
positive stem/progenitor cell marker,6,15 CD24, ER and CK19 as luminal lineage markers15,35,36 and 
ASMA as a myoepithelial lineage marker.36   
Representative examples of marker studies by immunoperoxidase staining in SCP and ICP 
cell lines are shown in Fig. 5.  All five SCP cell lines displayed a heterogeneous pattern of 
positivity with CD44; some colonies were fully positive, some fully negative and some others were 
composed of both positive and negative cells. CD44/CD24 double immunofluorescence studies 
with T47D cell line indicated that SCP cells produce also CD44+/CD24- stem/progenitor cells, as 
expected (data not shown). In sharp contrast, five of the seven ICP cell lines generated only fully 
positive CD44 colonies, indicating they never produced CD44- cells. One cell line was totally 
CD44-. Only one cell line displayed a pattern similar to that of SCP cell lines. The comparison of 
two subtypes indicated that the ability to generate both CD44+ and CD44- progeny is significantly 
associated with the SCP phenotype (p = 0.0046). All five SCP cell lines displayed heterogeneous, 
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but mostly positive ER immunostaining, whereas all seven ICP cell lines never generated ER+ 
cells. The expression of ER was also significantly associated with the SCP subtype (p = 0.0012). 
Furthermore, the ability to produce ASMA+ progeny was also significantly associated with the SCP 
subtype (p = 0.0046). The ICP cell lines did not generate ASMA+ cells, while four out of five SCP 
cell lines generated rare ASMA+ cells under low-density clonogenic conditions. Interestingly, the 
abundance of ASMA+ cells was much higher in the two SCP cell lines that were tested at high cell 
density (). This suggests that either the production of ASMA+ cells is 
enhanced at high cell density, or these myoepithelial-like cells have limited survival ability under 
long-term culture conditions. We did not find a strong association between the expression of CD24 
and CK19 markers and cell subtype. All five SCP cell lines and three ICP cell lines generated 
heterogeneously staining colonies for CD24 expression.  Similarly, all five SCP cell lines, as well 
as three ICP cell lines, expressed CK19, but homogenously.  
 
Typical features of senescent progenitor and immortal progenitor breast cancer cell lines 
 As summarized in Fig. 6, SCP and ICP subtype cell lines displayed several subtype-specific 
features. All SCP cell lines produced differ ntiated and senescent cells, in addition to putative 
CD44+/CD24- stem/progenitor cells. All of them produced ER+, and CD24+ luminal-like cells and 
most of them (n=4/5) also produced ASMA+ myoepithelial-like cells. In contrast, five of the seven 
ICP cell lines never produced CD44- cells, suggesting they cannot generate differentiated progeny 
under the experimental conditions tested.  In confirmation of this hypothesis, four ICP cell lines 
only produced CD44+/CD24-/ER-/CK19-/ASMA- stem/progenitor-like, but never differentiated 
cells. Furthermore, all seven ICP cell lines were unable to produce ASMA+ myoepithelial-like, 
ER+ luminal-like or SABG+ senescent cells. CD24 and CD19 luminal lineage markers were 
expressed in only three cell lines, one of which remained fully positive for CD44 stem/progenitor 
marker.  
Senescent and immortal cell progenitor breast cancer cell lines are phenocopies of luminal 
A/normal-like and basal/luminal B tumor subtypes 
 Distinct cell-type features associated with SCP and ICP subtypes suggest that they may be 
phenocopies of molecularly defined breast tumor subtypes.2-4,37 As the prognosis and therapeutic 
response of each subtype is different,3,4 we questioned whether we could assign SCP and ICP cell 
lines to known molecular subtypes of breast tumors. Using cell line and primary tumor gene 
expression datasets, we conducted hierarchical clustering analysis. The “intrinsic gene set” data 
generated by Sorlie et al.3 to classify breast tumors into five molecular subtypes was used to filter 
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cell line data generated by Charafe-Jauffret et al.25 A set of 175 genes was common between the 
two data sets. Sixty-eight tumors and 31 cell lines were subjected to pair-wise complete-linkage 
hierarchical clustering and distance measurements. This tumor-cell line combined analysis 
produced two major clusters. One cluster was composed of basal and luminal B subtype tumors and 
a group of cell lines that included five of six ICP cell lines. The other cluster included luminal A, 
ERBB2+ and normal-like subtype tumors and a set of cell lines that included all five SCP subtype 
cells. Four cell lines clustered with luminal A tumor subclass, and one cell line with normal-like 
subclass (Fig. 7a). A full list of clustered tumors and cell lines is provided in . 
Luminal A tumors clustering with our SCP subtype cell lines display the longest tumor-free, 
distant metastasis-free and overall survival rates. In contrast, basal and luminal B tumors clustering 
with our ICP subtype cell lines have the worst prognosis, with shorter tumor-free, distant 
metastasis-free and overall survival times.3 Our cluster analysis suggests that the ability to generate 
differentiated and senescent progeny characterises breast cancers with poor tumorigenicity, and that 
the resistance to differentiation and senescence is indicative of more aggressive tumorigenicity. We 
compared in vivo intrinsic tumorigenic behavior of three SCP (MCF-7, T47D and CAMA-1) and 
three ICP (BT-20, HCC1937 and MDA-MB-453) cell lines in CD1 “nude” mice. In order to 
compare the intrinsic tumorigenicity of SCP and ICP cell lines independent of external hormonal 
inteference, we set up experimental conditions to minimise such effects. As estrogen interfered with 
sponatenous senescence arrest in T47D SCP cell line (Fig. 3), male animals in the absence of 
estrogen complementation were used for tumorigenicity studies. Nine animals implanted with SCP 
cell lines did not develop tumors and remained tumor-free for at least 10 weeks. In contrast, seven 
out of eight animals implanted with ICP cell lines developed subcutaneous tumors within five 
weeks of cell injection (Fig. 7b). One animal injected with MDA-MB-453 ICP cell line, which died 
very shortly after cell injection, was excluded from the analysis. The difference of tumorigenicity 
between SCP and ICP cell lines was statistically significant (p = 0.0002). 
 
Discussion 
In recent years, phenotypic heterogeneity of breast cancers has been correlated with genetic and 
molecular heterogeneity.2,4 Breast cancer subtypes may represent cancers originating from different 
progenitor cells. Molecular and phenotypic heterogeneity and associated clinical manifestations of 
breast tumor subtypes have been related to the type of hypothetical tumor progenitor cells 
originating from a hypothetical mammary epithelial stem cell or from downstream progenitor 
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cells.1,5 This hypothesis has not been fully validated, mainly because a hierarchical map of cells 
involved in mammary epitheliogenesis has not yet been established.  
 To better understand phenotypic differences between different breast cancer subtypes, we 
applied senescence as a surrogate marker for the potential to generate terminally differentiated 
progeny. We completed these studies with markers for breast stem/progenitor and differentiated 
luminal and myoepithelial lineage cells. The use of low-density clonogenic conditions allowed us to 
follow up the fate of a large number of single-cell-derived progeny for each cell line studied. Using 
these approaches, we draw several important conclusions. First, breast cancer cell lines form two 
distinct groups of SCP and ICP subtypes. The SCP cell lines produce both non-senescent and 
senescent progeny, whereas ICP cell lines produce only non-senescent progeny. Second, SCP and 
ICP cell lines are exclusively ER+ and ER- cell lines, respectively. Senescence occurs as a result of 
ER loss associated with p21Cip1 induction. Experimental activation of ER by E2 protects from 
senescence, whereas its inactivation by tamoxifen aggravates it. Thus, senescence in ER-dependent 
cells appears to result from the loss of survival signals generated by transcriptional activity of ER. 
A similar type of senescence has been reported for lymphoma, osteosarcoma, and hepatocellular 
carcinoma tumors upon c-MYC inactivation.38 Third, SCP cells generate ER+, CD24+ or CK19+ 
luminal-like, as well as ASMA+ myoepithelial-like progeny. These findings strongly suggest that 
most, if not all, SCP cells have the capacity to give rise to two major types of differentiated cells 
that are found in normal mammary epithelium. In sharp contrast, ICP cells never produce ER+ 
luminal-like or ASMA+ myoepithelial-like cells. Indeed, some ICP cells generate only CD44+ 
stem/progenitor-like cells and never CD44-, CD24+, CK19+, ER+ or ASMA+ cells. These findings 
indicate that ICP cells have limited differentiation ability, at least under in vitro conditions. The 
differentiation ability of ICP cells appears to be lost completely or partially, so while they self-
renew as stem/progenitor-like cells, they do not differentiate fully. Fourth, SCP cell lines and 
luminal A/normal-like breast tumors form the same molecular cluster. This suggests that SCP cell 
lines are phenocopies of these relatively benign, antiestrogen-responsive luminal A tumors. The 
lack of tumorigenicity of SCP cell lines in “nude” mice correlates with better tumor-free and 
metastasis-free survival of patients with luminal A type tumors. The ICP cell lines cluster with 
luminal B/basal-like breast tumor subtypes, and they are highly tumorigenic, as expected for 
luminal B and basal-like tumors. Presently, it is unknown whether breast tumor subtypes that 
cluster with SCP or ICP cell lines are also composed of either differentiating or mostly self-
renewing stem/progenitor cells. Recent studies reported that breast tumors may contain only 
CD44+, or only CD24+ cells, as well as mixed cell populations, and that CD44+ tumor cells 
express many stem-cell markers.15,16 In addition, an association between basal-like breast cancer 
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and the presence of CD44+/CD24- cells has been established.16  
 The mechanisms of the differentiation block observed in ICP cell lines are not known. One 
might argue that cell lines that produce only CD44+, but never differentiation marker-positive cells 
cannot be defined as stem/progenitor cells by definition. However, such cell lines are not 
completely inert to differentiation stimuli, and may undergo differentiation under special 
conditions. For example, MDA-MB-231 and MDA-MB-468 cells (identified as ICP cell lines here) 
can be induced to differentiate into ER+ cells by Wnt5a treatment, and MDA-MB-231 cells become 
sensitive to tamoxifen.39 The same study also showed ER promoter sequences are methylated in 
these two ICP cell lines. Wnt5a treatment induces ER promoter demethylation, providing evidence 
for epigenetic mechanisms involved in differentiation programs of breast cancer cells.  
Most of the findings reported here are derived from in vitro studies performed with 
established cancer cell lines. Presently, it is unknown to what extent these findings are relevant also 
for breast tumors. We provide here some promising data that supports in vivo relevance of our 
conclusions. First, our cluster analyses associated the SCP cell types with luminal A and normal-
like breast tumors, whereas the ICP cell types shared similar gene expression profile with luminal 
B/basal-like breast tumors. Second, our tumorigenicity experiments with three different cell lines 
from each group clearly showed that ICP cell lines displayed high tumorigenicity, in contrast to 
SCP cell lines that were less tumorigenic under the same conditions.  The use of male animals 
without estrogen supplementation in these experiments allowed us to compare intrinsic tumorigenic 
potentials of SCP and ICP cell lines, with minimal interference of host animal estrogenic 
conditions. We preferred to use this model in order to maximise the contributions of cancer cell 
intrinsic features to the tumorigenic potential, with minimal interference of external hormonal 
factors. Therefore, the diffference in tumorigenic potential observed under our experimental 
conditions is likely to reflect in vivo behavior of cancer cells themselves, rather than their 
interaction with host hormonal factors. Obviously, ICP-like and SCP-like tumors in affected women 
may or may not display similar tumorigenic potentials depending on their hormonal status and 
treatment conditions. However, as most SCP-like luminal A or ER+ tumors are successfully treated 
with tamoxifen,41 their less aggressive behavior could be related to their highly effective senescence 
response to tamoxifen treatment, as shown here with T47D cells under in vitro conditions (Fig. 3). 
It will be interesting to examine whether the success of anti-estrogenic treatments is indeed 
associated with senescence induction in breast tumors. If this is indeed the case, senescence-
inducing treatments should be considered for breast cancer. 
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Conclusions 
Our analyses reveal that in vitro ability to generate senescent progeny permits discrimination 
between cells that share molecular and tumorigenic similarities with luminal A subtype breast 
tumors from cells related to basal/luminal B subtype tumors. We also provide in vitro evidence for 
classification of breast cancers into two major groups based on the ability to generate differentiated 
progeny. Taken together, our results show that less-tumorigenic SCP cell lines generate both 
luminal- and myoepithelial-like cells. In contrast, more tumorigenic ICP cell lines are defective in 
their ability to generate differentiated progeny.  Our findings may have prognostic relevance and 
serve as a basis for therapeutic induction of differentiation and senescence in breast cancer. 
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Figure legends 
Figure 1. Classification of breast cancer cell lines as senescent cell progenitor and immortal 
cell progenitor subtypes.  
(a) Examples of SABG staining for senescence of breast cancer cell line colonies obtained after 
plating for low-density clonogenic conditions in 6-well plates. Breast cancer cell lines (Table S1) 
were plated to obtain a few hundred colonies with 1-2 weeks of cell culturing and were subjected to 
SABG assay, followed by counterstaining with nuclear fast red (except ZR-75-1). Pictures were 
slightly resized to visualize all cells of a colony. T47D, BT-474, ZR-75-1, MCF-7 and CAMA-1 
generated mostly heterogeneous colonies with SABG+ and SABG- cells (shown here), but also 
fully negative or fully positive colonies. All other cell lines produced only SABG- colonies.  
(b) Classification of breast cancer cell lines as senescent cell progenitor (SCP) and immortal cell 
progenitor (ICP) subtypes by quantification of the ability to generate senescent progeny. Cell lines 
with a mean of SABG+ cells superior to 10% were termed SCP, and the other cell lines as ICP. 
Colonies that were generated and stained as described in (a) were counted manually to calculate % 
SABG+ cells. At least 10 colonies were counted for each cell line. T47D and BT-474 senescence 
data were reported previously [23].  Error bars represent mean ± SD. 
(c) SABG+ senescent cells display terminal growth arrest. Colonies were generated as described in 
(a), labeled with BrdU for 24h in the presence of freshly added culture medium, and subjected to 
SABG/BrdU double-staining (see Experimental Procedures). SABG+ cells are BrdU-, and vice 
versa. T47D-iso and BT-474-iso23 are clones derived from T47D and BT-474, respectively. Note 
that parental T47D and T47D-iso23 clones display similar staining features.  
Figure 2. Senescent cell progenitor phenotype is associated with p21Cip1 expression. 
(a) Four of five senescent SCP cell lines (top four from left) generate colonies with heterogeneous 
expression of p21Cip1, but not ICP cell lines. Colonies were immunostained for p21Cip1, with 
hematoxylin used as counterstain. Insets: magnified views of p21cip1+ cells. 
(b-e) p21Cip1 silencing inhibits the production of the terminally arrested progeny of SCP cells. T47D 
cells were infected with lentiviral vectors encoding p21Cip1 shRNA or scrambled shRNA to generate 
T47D-p21sh and T47D-scr stable cell lines, and tested for p21Cip1 knock-down by western blotting 
(b). Colonies were generated from respective cell lines, labeled with BrdU for 24h, immunostained 
for BrdU, and slightly counterstained with hematoxylin to visualize BrdU+ and negative cells. 
Insets: magnified views of cells (c). For quantification of % BrDU cells, individual colonies were 
manually counted. Each bar represents one colony (d). The silencing of p21Cip1 caused a significant 
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increase in % ratios of BrdU+ cells (e; p = 0.0043). Mean % BrdU+ cells (± SD) were calculated 
from data presented in (d). Error bars represent mean ± SD. Tub. = Tubulin. 
Figure 3. Generation of senescent cell progeny is controlled by estrogen receptor  
(a) SCP cells (T47D) express nuclear ER, but their senescent progeny do not, as compared to ICP 
cells (MDA-MB-231), which do not express ER at all. Colonies generated from T47D and MDA-
MB-231 cell lines, respectively, were co-stained for senescence by SABG and for ER expression by 
immunoperoxidase. MDA-MB-231 cells negative for both markers were counterstained with 
hematoxylin to visualize cells.  
(b-d) The production of senescent progeny in SCP cells is inhibited by estrogen (E2), but enhanced 
by tamoxifen (4OHT) treatment. After plating in low-density clonogenic conditions, T47D cells 
were grown in standard cell culture medium for seven days, followed by phenol-free DMEM 
complemented with charcoal-treated fetal calf serum for two days, then cultivated for four days in 
the presence of E2, OHT, or an ethanol vehicle (control). Colonies were subjected to SABG 
staining (b). Total and SABG+ and SABG- cells were counted from 20 randomly selected colonies 
(c), and mean % SABG+ cells (± SD) w re calculated (d). Error bars represent mean ± SD. The 
inhibition of senescence by E2 and its activation by OHT was statistically significant when 
compared to ethanol-complemented control cells (p values 0.0093, 0.0002 and <0.0001 for 10-9M 
E2, 10-7 M OHT and 10-6 M OHT, respectively). 
Figure 4. Overexpression of estrogen receptor inhibits the production of terminally arrested 
progeny.  
ER-overexpressing (ER-5, ER-7, ER-26) and control (C-8, C-10, C-11) clones were established 
from T47D cells and tested for ER expression by western blotting using decreasing amounts of total 
proteins. Calnexin was used as loading control (a). Colonies were generated, labeled with BrdU for 
24h and immunostained for BrdU (Fig. S3). For quantification of % BrDU cells, individual colonies 
were manually counted (b), and mean % BrdU+ cells were calculated (c). Error bars represent mean 
± SD. Estrogen receptor overexpression caused a significant increase in % ratio of BrdU+ cells 
(*three ER clones versus three controls; p = 0.034). 
Figure 5. Senescent cell progenitor and immortal cell progenitor subtypes greatly differ in 
their ability to differentiate into luminal and myoepithelial lineage cells. 
Senescent cell progenitor and immortal cell progenitor subtype cell lines were studied by 
immunoperoxidase staining using CD44 and markers for luminal epithelial (CD24, CK19, ER) and 
myoepithelial (ASMA) lineages. Insets: magnified views of positive cells. Both subtypes have 
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CD44+ cells. Senescent cell progenitor cell lines produce CD44- cells, CD24+, CK19+ or ER+ 
luminal-like and ASMA+ myoepithelial-like cells (except ZR-75-1 for myoepithelial-like cells). 
Immortal cell progenitor cell lines produce only CD44+/CD24-/CK19-/ER-/ASMA- 
stem/progenitor cells (MDA-MB-231, MDA-MB-157, HCC-1937, BT-20), or cannot generate ER+ 
luminal-like and ASMA+ myoepithelial-like cells (MDA-MB-468, SK-BR-3, MDA-MB-453).  
Figure 6. Typical features of senescent progenitor and immortal progenitor breast cancer cell 
lines. 
Figure 7. Senescent and immortal cell progenitor breast cancer cell lines are phenocopies of 
luminal A/normal-like and basal/luminal B tumor subtypes. 
(a) Unsupervised hierarchical clustering of breast tumor and cell line gene expression data from 
Sorlie et al [2] and Charafe-Jauffret et al [25]. Dendrogram displaying the relative organization of 
tumor and cell line data demonstrates that ICP cell lines cluster with basal and luminal A tumors in 
the same branch, except for MDA-MB-453. Senescent cell progenitor cell lines cluster with luminal 
A (BT-474, CAMA-1, MCF-7, T47D) and normal-like tumors (ZR-75-1). No data was available for 
MDA-MB-468. A dendrogram with sample IDs is provided in Supplementary Fig. S6. The 
“intrinsic gene set” data generated by Sorlie et al [2] was used to filter cell line data generated by 
Charafe-Jauffret et al [25]. A set of 175 genes was common between the two data sets. Sixty-eight 
tumors and 31 cell lines were subjected to pair-wise complete-linkage hierarchical clustering and 
distance measurements. 
(b) Immortal cell progenitor cell lines, but not senescent cell progenitor cell lines, form 
subcutaneous tumors in “nude” mice. Chart displays tumor-free survival following subcutaneous 
injection of 5x106 cells. Three SCP (MCF-7, T47D and CAMA-1) and three ICP (BT-20, HCC1937 
and MDA-MB-453) cell lines were used in triplicate. One animal died shortly after the injection of 
MDA-MB-453 cells. The difference in tumorigenicity was statistically significant (p = 0.0002). 
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Table 1: Gene clusters, genetic mutations and epigenetic changes of breast cancer cell lines used in this study  
Cell Line Gene 
Cluster 
PIK3CA CCND1 
 
ERBB2 
 
KRAS 
BRAF 
TP53 
 
CDKN2A 
 
RB1 
 
PTEN 
 
NF2 
 
T47D L M/+    M/- met    
BT474 L M/+ A A  M/- RNA (-)    
ZR-75-1 L  A   +/+ met  M/-  
MCF7 L M/+    +/+ M/-    
CAMA-1 L  A   M/- +/+  M/+  
MDA-MB-453 L M/+    +/+ +/+  M/?  
SK-BR-3 L   A  M/- unmet    
BT-20 BaA M/M     M/-  M/-  
MDA-MB-468 BaA     M/ - +/+ M/- M/?  
HCC1937 BaA +/+    M/- +/+  -/-  
MDA-MB-231 BaB    M/+ 
M/+ 
M/- M/-   M/- 
 
MDA-MB-157 BaB +/+    M/- +/+    
References 21 Sanger1 21 21 Sanger1 Sanger1, 
44 
Sanger1, 
21, 43 
Sanger1 Sanger1, 
42 
Sanger1 
 
A, amplified; BaA, basal A; BaB, Basal B; L, luminal; M, mutated; met, promoter methylated; unmet, promoter unmethylated; +/+, wild-type;  -/-, 
homozygous deletion; ?, unknown. 1From Sanger COSMIC data (http://www.sanger.ac.uk/genetics/CGP/cosmic/). 
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Reprogramming of replicative senescence
in hepatocellular carcinoma-derived cells
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Tumor cells have the capacity to proliferate indefinitely that is
qualified as replicative immortality. This ability contrasts with the
intrinsic control of the number of cell divisions in human somatic
tissues by a mechanism called replicative senescence. Replicative
immortality is acquired by inactivation of p53 and p16INK4a genes
and reactivation of hTERT gene expression. It is unknown whether
the cancer cell replicative immortality is reversible. Here, we show
the spontaneous induction of replicative senescence in p53-and
p16INK4a-deficient hepatocellular carcinoma cells. This phenome-
non is characterized with hTERT repression, telomere shortening,
senescence arrest, and tumor suppression. SIP1 gene (ZFHX1B) is
partly responsible for replicative senescence, because short hairpin
RNA-mediated SIP1 inactivation released hTERT repression and
rescued clonal hepatocellular carcinoma cells from senescence
arrest.
immortality  liver cancer  SIP1  telomerase  p53
Tumor cells are clonal (1), and tumorigenesis usually requiresthree to six independent mutations in the progeny of pre-
cancerous cells (2). For this to occur, preneoplastic somatic cells
would need to breach the replicative senescence barriers. Rep-
licative senescence is a telomere-dependent process that sets a
limit to the successive rounds of cell division in human somatic
cells (3). Progressive telomere shortening is observed in almost
all dividing normal cells. This phenomenon is linked to the lack
of efficient hTERT expression that is observed in most human
somatic cells (3). Replicative senescence (permanent growth
arrest also called M1 stage) is believed to be initiated by a DNA
damage-type signal generated by critically shortened telomeres,
or by the loss of telomere integrity, leading to the activation of
cell cycle checkpoint pathways involving p53, p16INK4a, andor
retinoblastoma (pRb) proteins (4, 5). In the absence of func-
tional p53 and p16INK4apRb pathway responses, telomeres
continue to shorten resulting in crisis (also called M2 stage).
Cells that bypass the M2 stage by reactivating hTERT expression
gain the ability for indefinite cell proliferation, also called
immortality (3, 4, 6). There is accumulating evidence that cancer
cells undergo a similar process during carcinogenesis to acquire
immortality. Telomerase activity associated with hTERT reex-
pression is observed in 80% of human tumors (7), and senes-
cence controlling p53 and p16INK4A genes are commonly inacti-
vated in the majority of human cancers (8). Moreover,
experimental transformation of normal human cells to tumor
cells requires hTERT-mediated immortalization, as well as
inactivation of p53 and pRb genes (9).
Aberrant expression of hTERT, together with the loss of p53
and p16INK4apRb control mechanisms, suggests that the repli-
cative immortality is a permanent and irreversible characteristic
of cancer cells. Although some cancer cells may react to extrinsic
factors by a senescence-like stress response, this response is
immediate, telomere-independent, and cannot be qualified as
replicative senescence (10). Experimental inactivation of telom-
erase activity in cancer cells mostly results in cell death (11),
whereas ectopic expression of p53, p16INK4a, or pRb provokes an
immediate senescence-like growth arrest or cell death (10).
Thus, to date there is no experimental evidence for spontaneous
reprogramming of replicative senescence in immortalized cancer
cells. Using hepatocellular carcinoma (HCC)-derived Huh7 cells
as a model system, here we show that cancer cells with replicative
immortality are able to spontaneously generate progeny with
replicative senescence. Thus, we provide preliminary evidence
for the reversibility of cancer cell immortality. The replicative
senescence of cancer cells shares many features with normal cell
replicative senescence such as repression of hTERT expression,
telomere shortening, and permanent growth arrest with mor-
phological hallmarks of senescence. However, the p53 gene is
mutated, whereas p16INK4a promoter is hypermethylated in these
cells. Thus, we show that fully malignant and tumorigenic HCC
cells that display aberrant hTERT expression and lack functional
p53 and p16INK4a genes are able to revert from replicative
immortality to replicative senescence by an intrinsic mechanism.
Furthermore, we demonstrate that the SIP1 gene, encoding a
zinc-finger homeodomain transcription factor protein involved
in TGF- signaling (12, 13) and hTERT regulation (14), serves
as a molecular switch between replicative immortality and
replicative senescence fates in HCC cells.
Results
When analyzing clones from established cancer cell lines, we
observed that some clones change morphology and cease pro-
liferation at late passages with features reminiscent of cellular
senescence (data not shown). We reasoned that this could be an
indication for generation of progeny programmed for replicative
senescence. We surveyed a panel of HCC and breast carcinoma
cell lines and hTERT-immortalized human mammary epithelial
cells (hTERT-HME). Plated at low clonogenic density, cells
were maintained in culture until they performed 6–10 popula-
tion doublings (PD), and tested for senescence-associated -
galactosidase (SABG) activity (15). Different cancer cell lines
generated progeny with greatly contrasting SABG staining
patterns. The first group, represented here by HCC-derived
Huh7 and breast cancer-derived T-47D and BT-474 cell lines,
generated heterogeneously staining colonies. Cells of some
colonies were mostly positive for SABG, but others displayed
significantly diminished or complete lack of staining (Fig. 1A).
The second group, represented by HCC-derived Hep3B and
Mahlavu, and hTERT-HME generated only SABG-negative
colonies (Fig. 1B). Manual counting of randomly selected col-
onies demonstrated that mean SABG-labeling indexes for Huh7,
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T-47D and BT-474 progenies were 45  23%, 40  29%, and
33  7%, respectively (Fig. 1C, lanes 1–3). In contrast, Hep3B,
Mahlavu, and hTERT-HME progenies displayed 3  3%
mean SABG-labeling indexes (Fig. 1C, lanes 4–6). Clones from
representative cell lines were expanded and subjected to the
same analysis. SABG-staining patterns of all clones tested were
closely similar to the patterns of their respective parental cell
lines. For example, mean SABG staining indexes of Huh7-
derived clones were 14  15%, 47  27%, and 17  11% (Fig.
1C, lanes 7–9), whereas Hep3B-derived clones generated 2 
3% SABG-positive progenies (Fig. 1C, lanes 10–12). We spec-
ulated that the first group of cell lines comprised progenies in
different stages of replicative senescence process at the time of
analysis, whereas the second group of cell lines were composed
mostly of immortal cells. The results obtained with the first
group were unexpected. These cell lines have been established
20 years ago (16–18) and expanded in culture over many years,
with PD well beyond the known senescence barriers for normal
human cells (3), but they were still capable of generating
presumably senescent progeny.
The study of a potentially active replicative senescence pro-
gram in the progeny of immortal cancer cell lines requires the
long-term follow up of single cell-derived clones. To this end, we
chose to focus our investigations on Huh7 cell line. We expanded
different Huh7-derived clones in long-term culture and exam-
ined their potential to undergo replicative senescence. Some
clones performed 100 PD in culture with stable proliferation
rates and heterogeneous SABG staining, whereas others sus-
tained a limited number of PD, then entered a growth arrest
phase with full SABG staining patterns. For example, C3 clone
performed only 80 PD, whereas C1 clone replicated 150 PD.
Permanently arrested C3 cells (PD 80) displayed enlarged size,
f lattened shape, and fully positive SABG staining, whereas early
passage C3 (PD 57) and C1 (PD 179) cells displayed normal
morphology with heterogeneous SABG staining (Fig. 2AUpper).
Normal human cells at replicative senescence (M1) are refrac-
tory to mitotic stimulation and display 5% BrdUrd index (19).
Growth-arrested C3 cells displayed very low BrdUrd staining
(2  2%), in contrast to early passage C3 and late passage C1
cells, which exhibited 89  6%, and 96  3% BrdUrd indexes,
respectively (Fig. 2A Lower). Senescent C3 cells remained
growth arrested, but alive when maintained in culture for at least
3 months, with no emergence of immortal clones (data not
shown).
Biological mechanisms of replicative senescence observed
here are of particular interest, because senescence-regulatory
p53 is inactivated (20–22) and p16INK4a promoter is hypermethy-
lated (23) in Huh7 cells. Accordingly, there was no change in p53
levels, whereas the low level p16INK4a expression did not in-
crease, but decreased in senescent C3 (PD 80) cells, when
compared to presenescent C3 (PD 57) or immortal C1 (PD 179)
cells. Retinoblastoma protein (pRb) displayed partial hypophos-
Fig. 1. Established human cancer cell lines generate senescence-associated
-galactosidase (SABG)-expressing progeny. (A) Representative pictures of
HCC (Huh7) and breast cancer (T-47D and BT-474) cell lines that generate both
SABG-positive (Upper) and SABG-negative (Lower) colonies. (B) Representa-
tive pictures of HCC (Hep3B and Mahlavu) and telomerase-immortalized
mammary epithelial (hTERT-HME) cell lines that generate only SABG-negative
colonies. Cells were plated at clonogenic density to generate colonies with
6–10 population doublings, and stained for SABG activity (blue), followed by
eosin counterstaining (red). (C) Quantification of SABG-positive cells in colo-
nies. Randomly selected colonies (n 10) obtained from parental (lanes 1–6)
cell lines and expanded clones (lanes 7–12) were counted to calculate the
average % SABG positive cells per colony (% SABG index). Lanes 1–6 designate
Huh7, T-47D, BT-474, Hep3B, Mahlavu, and hTERT-HME, respectively. Lanes
7–9 are Huh7-derived C1, C3, and C11 clones, and lanes 10–12 are Hep3B-
derived 3B-C6, 3B-C11, and 3B-C13 clones. Error bars indicate SD.
Fig. 2. p53-and p16INK4a-deficient Huh7 cells generate progeny that un-
dergo in vitro and in vivo replicative senescence resulting in loss of tumori-
genicity. (A) Huh7-derived clones C3 and C1 were tested for replicative senes-
cence arrest by SABG and BrdUrd staining at different passages. Presenescent
C3 and immortal C1 cells display low SABG staining (Upper) and high BrdUrd
incorporation (Lower), whereas senescent C3 cells are fully positive for SABG
(Upper) and fail to incorporate BrdUrd into DNA after mitogenic stimuli
(Lower). (B) p53 and p16INK4a protein levels show no increase in senescent C3
cells, compared to presenescent C3 and immortal C1 cells, but senescent C3
cells display partial hypophosphorylation of pRb. Calnexin was used as a
loading control. Proteins were tested by Western blotting. PS, presenescent
(PD 57); S, senescent (PD 80); I, immortal (PD 179). (C) C1 cells (black line) were
fully tumorigenic, but C3 cells (red line) were not in nude mice. (D) C1 tumors
displayed low SABG staining (Upper Right), whereas implanted C3 cells re-
maining at the injection site are fully positive for SABG in situ (Upper Left), as
well as after short-term in vitro selection (Lower). Animals were injected with
presenescent C3 (PD 59) and immortal C1 (PD 119) cells, and tumors and
nontumorigenic cell samples were collected at day 35 and analyzed.
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phorylation in senescent C3 cells, apparently in a p53- and
p16INK4a-independent manner (Fig. 2B). Cyclin E and A levels
were also decreased, but p21cip1 levels were elevated in both
presenescent and senescent C3 cells (Fig. 5A, which is published
as supporting information on the PNAS web site). Cyclin D1,
CDK4, and CDK2 protein levels (Fig. 5A) and p14ARF transcript
levels (Fig. 5B) did not change.
Cancer cell senescence that we characterized here shared
many features with normal cell replicative senescence (3), except
that it was not accompanied with wild-type p53 or p16INK4a
induction. However, in vivo relevance of the replicative senes-
cence observed in cell culture is debated (6). Therefore, we
compared in vivo replicative potentials of C3 (PD 59) and C1
(PD 119) cells in CD-1 nude mice. C3 cells did not form visible
tumors, whereas C1 cells were fully tumorigenic in the same set
of animals (Fig. 2C), like parental Huh7 cells (data not shown;
ref. 24). C1 tumors collected at day 35 displayed scattered but
low-rate SABG-positive staining, but remnant C3 cell masses
collected from their injection sites were fully SABG-positive
(Fig. 2D Upper). For confirmation, these remnants were re-
moved from two different animals, passaged twice in cell culture
for selection, and examined. Nearly all cells displayed senescence
features including enlarged size, f lattened shape, and highly
positive SABG staining (Fig. 2D Lower). We concluded that loss
of C3 tumorigenicity was due to replicative senescence in vivo.
Replicative senescence, also called telomere-dependent se-
nescence is associated with progressive telomere shortening due
to inefficient telomerase activity (3). When compared to paren-
tal Huh7 cells, presenescent C3 cells at PD 57 had telomeres that
have already been shortened to 7 kbp from 12 kbp. These
cells eroded their telomeres to5 kbp at the onset of senescence.
In contrast, immortal C1 clone (PD 179) telomeres did not
shorten (Fig. 3A). These observations showed a perfect corre-
lation with telomerase activity and hTERT expression. Immortal
C1 cells displayed robust telomerase activity, whereas both
presenescent and senescent C3 cells had no detectable telom-
erase activity (Fig. 3B). Accordingly, the expression of hTERT
gene was high in C1, but barely detectable in C3 cells (Fig. 3C).
Thus, senescence observed with C3 cells was characterized with
the loss of hTERT expression and telomerase activity, associated
with telomere shortening.
Mechanisms of hTERT expression are presently unclear, but
several genes including SIP1, hSIR2, c-myc, Mad1, Menin, Rak,
and Brit1 have been implicated (14, 25). Therefore, we analyzed
their expression in C1 and C3 clones. All tested genes, except
SIP1, were expressed at similar levels in both C1 and C3 clones,
independent of hTERT expression (Fig. 6, which is published as
supporting information on the PNAS web site). SIP1 transcripts
were undetectable in C1 cells, but elevated in C3 cells, moder-
ately in presenescent, but strongly in senescent stages (Fig. 3C).
We verified these findings with another Huh7-derived clone
(G12) that displayed replicative senescence resulting in perma-
nent cell proliferation arrest. Like C3, presenescent G12 cells
that displayed low SABG staining with high BrdUrd index (98
1%), became fully positive for SABG, and nearly negative for
BrdUrd (3  2%) at the onset of senescence (Fig. 7, which is
published as supporting information on the PNAS web site).
Presenescent G12 cells displayed only a weak hTERT repression
associated with a slight increase in SIP1 expression, whereas
SIP1 was strongly elevated in hTERT-negative senescent cells
(Fig. 3D). Thus, there was a close correlation between SIP1
expression and hTERT repression in all Huh7 clones tested. The
analysis of SIP1 and hTERT expression in primary HCCs and
their corresponding nontumor liver tissues confirmed this rela-
tionship. SIP1 transcript levels were high, but hTERT expression
was low in nontumor liver tissues, whereas respective HCC
tumors displayed diminished SIP1 expression associated with
up-regulated hTERT expression (Fig. 3E).
The SIP1 gene (Zinc finger homeobox 1B; ZFHX1B) en-
codes a transcriptional repressor protein that interacts with
SMAD proteins of the TGF- signaling pathway and CtBP
corepressor (12, 13). This gene has recently been implicated in
TGF--dependent regulation of hTERT expression in breast
cancer cells (14). Our observations implicated SIP1 gene as a
candidate regulator of replicative senescence in HCC cells. To
investigate whether SIP1 expression constitutes a protective
barrier against hTERT expression and senescence bypass, we
constructed SIP1 short hairpin RNA (shRNA)-expressing
plasmids, based on a reported effective SIP1 siRNA sequence
(14). SIP1 shRNA was expressed by using either G-418-
resistance plasmid pSuper.retro.neoGFP or puromycin-
resistance plasmid pSUPER.puro (see shRNA in Methods).
Presenescent C3 cells at PD 75 were used for transfections, 3–4
weeks before expected senescence arrest stage.
pSuper.retro.neoGFP-based SIP1 shRNA suppressed the
accumulation in SIP1 when expressed transiently (Fig. 4A, day
5). This resulted in a weak increase in hTERT expression.
Transfected cells were maintained in culture in the presence of
500 gml G-418 and observed for 30 days. At this period, C3
cells transfected with a control plasmid reached senescence-
arrested stage with further up-regulation of SIP1 expression
(Fig. 4A, day 30) and resistance to BrdUrd incorporation after
mitogenic stimuli (BrdUrd index  3  1%; Fig. 4B Upper
Left). In sharp contrast, SIP1 shRNA-transfected cells lost
Fig. 3. C3 clonal cells undergo telomere-dependent replicative senescence
associated with SIP1 expression and hTERT repression. SIP1 expression is lost,
whereas hTERT is induced in primary HCC tumors. (A) Genomic DNAs from
parental Huh7 and immortal C1 cells display long telomeres, whereas C3
telomeres are progressively shortened in presenescent and senescent stages,
respectively. Equal amounts of genomic DNAs were blotted with a telomere
repeat probe. C. Low, short telomere control DNA. (B) Presenescent and
senescent C3 cells have lost telomerase activity, as measured by TRAP assay.
Telomerase activity was shown as % value of test samples ( SD) compared to
‘‘high positive’’ control sample. (C) hTERT expression as tested by RT-PCR was
high in immortal C1, but decreased to weakly detectable levels in C3 cells.
Inversely, SIP1 expression tested by RT-PCR was undetectable in C1 cells, but
showed a progressive increase in presenescent and senescent C3 cells. (D)
Inverse relationship between SIP1 and hTERT expression was confirmed with
another senescence-programmed Huh7 clone named G12 (for SABG and
BrdUrd assays, see Fig. 7). hTERT expression in G12 showed a slight decrease in
presenescent stage, followed by a loss at the onset of senescence. Inversely,
the expression of SIP1 gene was weakly positive in presenescent G12, but
highly positive in senescent G12 cells. C1 was used as control. PS, presenescent;
S, senescent; I, immortal. (E) Negative correlation between hTERT and SIP1
expression in primary tumors (T) and nontumor liver tissues (NT).
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SIP1 expression and up-regulated hTERT transcripts (Fig. 4A,
day 30). Furthermore, SIP1-inactivated cells escaped senes-
cence, as evidenced with 70 9% BrdUrd index (Fig. 4B Upper
Right). Morphologically, SIP1 shRNA-transfected cells formed
proliferating clusters, whereas cells transfected with control
plasmid displayed hallmarks of senescence such as scattering,
enlargement, and multiple nuclei (Fig. 4B Lower). Twelve
independent clones were selected from SIP1 shRNA-
transfected C3 cells. All but one of these clones have per-
formed so far 15 PD beyond the expected senescence barrier
(data not shown). As an additional confirmatory assay, C3 cells
were transfected with the puromycin-selectable pSUPER.puro-
based SIP1 shRNA vector and subjected to puromycin selec-
tion. SIP1 shRNA-transfected cells survived and formed large
number of colonies after 30 days of puromycin selection. In
contrast, no surviving colony was obtained from cells trans-
fected with the control plasmid, as expected (Fig. 4C).
Discussion
Our observations provide experimental evidence for the gen-
eration of senescence-arrested clones from immortal HCC and
breast cancer cell lines. Detailed analysis of clones from
HCC-derived Huh7 cell line further indicates that what we
observe is a replicative senescence, but not a stress-induced
premature senescence-like arrest. Clonal C3 cells displayed
telomerase repression, progressive telomere shortening, and
permanent growth arrest after 80 PD with senescence-
associated morphological changes and positive SABG stain-
ing. Similar changes have also been observed with G12,
another independently derived clone. Thus, we demonstrate
that immortal cancer cells have the intrinsic ability to repro-
gram the replicative senescence. As expected, this shift in cell
fate results in a complete loss of tumorigenicity. The replica-
tive senescence arrest that we identified with clonal C3 cells
was not accompanied with the induction of the p53, p16INK4a,
p14ARF, or p21Cip1 gene. The nonparticipation of p53 and
p16INK4a to the senescence arrest described here was expected,
in the light of published observations showing that Huh7 cells
express a mutant p53 protein (20–22) and they are deficient in
p16INK4a expression (23). Although the levels of p21Cip1 protein
displayed a slight increase in C3 cells, this was not related to
senescence arrest, as early passage proliferating C3 cells also
displayed this slight increase (Fig. 5). The early loss of hTERT
expression in this clone could contribute to early p21Cip1
up-regulation, because hTERT is known to down-regulate
p21Cip1 promoter activity (26). p53, p16INK4a, p14ARF, and
p21Cip1 form a group of replicative senescence-related cell
cycle checkpoint genes. The lack of induction of these genes in
senescence-arrested C3 cells clearly indicates that there are
additional genes involved in senescence arrest in these tumor-
derived cells.
The loss of hTERT expression in senescence programmed
clones prompted us to analyze the expression of genes that have
been implicated in hTERT regulation. Among seven candidate
genes studied, only one, the SIP1 gene, displayed a differential
expression between immortal and senescence-programmed
clones. This gene has been identified as a mediator of TGF--
regulated repression of hTERT expression in a breast cancer cell
line, although it was not effective in an osteosarcoma cell line
(14). In our studies, SIP1 was not expressed in immortal hTERT-
expressing C1 clone, but expressed in senescence-programmed
hTERT-repressed C3 and G12 clones (Fig. 3 B and C). Further-
more, experimental depletion of SIP1 transcripts resulted in
hTERT up-regulation in C3 clonal cells (Fig. 4A). This effect has
been confirmed by using SKHep1, another HCC cell line (data
not shown). Thus, we demonstrate that the SIP1 gene acts as an
hTERT repressor in HCC cells. More importantly, we also
showed the bypass of senescence arrest after functional inacti-
vation of SIP expression by shRNA in senescence-programmed
C3 clonal cells. In contrast to C3 cells transfected with a control
plasmid, SIP1 shRNA-treated cells displayed continued prolif-
eration beyond PD 80 as evidenced by 70% BrdUrd incorpo-
ration index, and formation of large number of colonies. Se-
lected shRNA-transfected clones from these experiments have
already performed15 PD beyond the senescence barrier. Thus,
our findings indicate that the functional inactivation of SIP1 in
senescence-programmed cancer cells is sufficient to bypass
senescent arrest.
SIP1 is a zinc finger and homeodomain containing tran-
scription factor that exerts a repressive activity by binding to
CACCT sequences in regulatory elements of target genes (12,
27). The SIP1 gene is expressed at high levels in almost all
human somatic tissues tested, including liver (28). Therefore,
we also performed comparative analysis of hTERT and SIP1
expression in nontumor liver and primary HCC tissues. SIP1
Fig. 4. ShRNA-mediated down-regulation of endogeneous SIP1 transcripts
releases hTERT repression and rescues C3 cells from senescence arrest. (A) At
day 5 after transfection, SIP1 shRNA-transfected cells (Sh-SIP1) show decreased
expression of SIP1 and weak up-regulation of hTERT expression. At day 30, the
expression of SIP1 is lost completely, and hTERT expression is stronger. (B) Cells
transfected with empty vector (Control) are senescence-arrested as evidenced
by resistance to BrdUrd incorporation (Upper Left) and morphological
changes (Lower Left), but cells transfected with SIP1 shRNA vector (Sh-SIP1)
escaped senescence arrest as indicated by high BrdUrd index (Upper Right)
and proliferating cell clusters (Lower Right). (C) Colony-forming assay shows
that C3 cells formed large number of colonies following puromycin selection
after transfection with a puromycin-resistant SIP1-shRNA-expressing plasmid
(Right), whereas cells transfected with empty vector did not survive (Left).
SIP1 shRNA was expressed by using either G-418-resistance plasmid
pSuper.retro.neoGFP (A and B) or puromycin-resistance plasmid pSUPER.
puro (C). Presenescent C3 cells at PD 75 were transfected with either SIP1
shRNA-expressing or empty plasmid vectors, maintained in culture in the
presence of appropriate selection media and tested at days 5 (A) and 30 (A–C).
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was strongly positive in nontumor liver samples, but its ex-
pression was significantly decreased in corresponding HCC
samples. Inversely, hTERT expression was negative or low in
nontumor liver samples, but highly positive in HCC tumors
(Fig. 3E). We also detected complete loss of SIP1 expression
in 5 of 14 (36%) of HCC cell lines (data not shown). Taken
together with in vitro studies, these observations strongly
suggest that SIP1 acts as a tumor suppressor gene in HCC.
Although SIP1, as a repressor of E-cadherin promoter, has
been suggested to be a promoter of invasion in malignant
epithelial tumors (29), a tumor suppressive activity by the
repression of hTERT and inhibition of senescence arrest is not
precluded.
Hepatocellular carcinoma is one of the most common
cancers worldwide. Liver cirrhosis is the major etiology of this
tumor with limited therapeutic options (30, 31). Telomere
shortening and senescence play a major role in liver cirrhosis,
from which the neoplastic HCC cells emerge with high rates of
telomerase reactivation (32). Furthermore, p53 and p16INK4a
are the most frequently inactivated genes in these tumors. This
fact enhances the importance of our findings for potential
therapeutic applications of replicative senescence program-
ming in HCC.
Methods
Tissues, Cells, and Clones. Snap-frozen HCC and nontumor liver
tissues were used. HCC and breast cancer cell lines T-47D
(ATCC) and BT-474 (ATCC) were cultivated as described (33).
hTERT-HME cells (Clontech) were cultivated in DMEM
Ham’s F-12 (Biochrom) containing insulin (3.5 gml), EGF
(0.1 ngml), hydrocortison (0.5 gml), and 10% FBS (Bio-
chrom). Huh7- and Hep3B-derived isogenic clones were ob-
tained by either G-418 selection after transfection with neomy-
cin-resistance pcDNA3.1 (Invitrogen) or pEGFP-N2 (Clontech)
plasmids, or by low-density cloning. Huh7-derived isogenic
clones C1 and C3 were obtained with pCDNA3.1, and G12 with
pEGFP-N2. Huh7-derived C11, and Hep3B-derived 3B-C6,
3B-C11 and 3B-C13 were obtained by low-density cloning. Cells
transfected with calcium phosphateDNA-precipitation method
were cultivated in the presence of geneticin G-418 sulfate (500
gml; GIBCO), and isolated single cell-derived colonies were
picked up by using cloning cylinders and expanded in the
presence of 200 gml geneticin G-418 sulfate. For low-density
cloning, cells were plated at 30 cells per cm2 and single-cell
derived colonies were expanded. Initial cell stocks were pre-
pared when total number of cells became 1–3  107, and the
number of accumulated population doubling (PD) at this stage
was estimated to be 24, assuming that the progeny of the initial
colony-forming cells performed at least 24 successive cell divi-
sions until that step. Subsequent passages were performed every
4–7 days, and the number of additional PD was determined by
using a described protocol (34).
Low-Density Clonogenic Assay. Cells (30–50 per cm2) were plated
in six-well plates and grown 1–3 weeks to obtain isolated colonies
formed with 100–1,000 cells. The medium was changed every 4
days, and colonies were subjected to SABG staining (see below).
In Vivo Studies. Cells were injected s.c. into CD-1 nude mice
(Charles River Breeding Laboratory). Tumors and nontumori-
genic cells at the injection sites were collected at day 35 and
analyzed directly or after in vitro culture by SABG assay (see
below). These experiments have been approved by the Bilkent
University Animal Ethics Committee.
SABG Assay. SABG activity was detected by using a described
protocol (15). After DAPI or eosin counterstaining, SABG-
positive and negative cells were identified and counted.
BrdUrd Incorporation Assay. Subconfluent cells were labeled with
BrdUrd for 24 h in freshly added culture medium and tested as
described (33), using anti-BrdUrd antibody (Dako) followed by
tetramethylrhodamine B isothiocyanate-labeled secondary an-
tibody (Sigma). DAPI (Sigma) was used for counterstaining.
Immunoblotting. Antibodies against cyclin D1, CDK4, CDK2,
p21Cip1, pRb (all from Santa Cruz Biotechnology), cyclin E
(Transduction), cyclin A (Abcam), p16INK4a (Abcam), p53 (clone
6B10; ref. 35), and calnexin (Sigma) were used for immunoblot-
ting as described (33).
RT-PCR.RT-PCR expression analysis was performed as described
(33), using primers listed in Table 1, which is published as
supporting information on the PNAS web site.
TRAP and Telomere Length Assays. Telomerase activity and telo-
mere length assays were performed by using TeloTAGGG
Telomerase PCR ELISAPLUS and TeloTAGGG Telomere
Length Assay (Roche Diagnostics), following kit instructions.
shRNA. SIP1-directed shRNA was designed according to a pre-
viously described effective siRNA sequence (14) using the
pSUPER RNAi system instructions (Oligoengine) and cloned
into pSuper.retro.neoGFP and pSUPER.puro (Oligoengine),
respectively. SIP1 shRNA-encoding sequence was inserted
by using 5-GATCCCCCTGCCATCTGATCCGCTCTT-
TCAAGAGAAGAGCGGATCAGATGGCAGTTTTTA-3
(sense) and 5-AGCTTAAAAACTGCCATCTGATCCGC-
TCTTCTCTTGAAAG AGCGGATCAG ATGGCAGGGG-3
(antisense) oligonucleotides.
The integrity of the inserted shRNA-coding sequence has been
confirmed by nucleic acid sequencing of recombinant plasmids.
Clone C3 cells were transfected with calcium phosphate precipita-
tion method, using either pSuper.retro.neoGFP-based or pSU-
PER.puro-based SIP1 shRNA expression plasmid, and cells were
maintained in the presence of 500 gml geneticin G-418 sulfate
and 2 gml puromycin (Sigma), respectively. Empty vectors were
used as control. Media changed every 3 days, and cells were tested
at days 5 and 30.
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